Podcasts about scientific advisory board

Send us a textDr. Samir Khleif, MD is CEO of Georgiamune ( https://www.georgiamune.com/team ), a private, science and discovery clinical stage immunotherapeutic biotechnology company focused on reprogramming immune signaling pathways to redirect the immune system to fight diseases.  Dr. Khleif is a pioneer in the field of immunotherapy. He is a medical oncologist, immunologist, innovator, and entrepreneur, as well as a transformational executive in health care and biomedical research.Prior to becoming CEO of Georgiamune, Dr. Khleif served in different academic and leadership positions. He was a National Cancer Institute (NCI)/National Institutes of Health (NIH) scientist and Chief of the NCI Cancer Vaccine Section, where he led the development of pioneering immune-oncology and cancer vaccines into clinical trials. As a national and international academic leader, and detailed by the US government, he served as the founding director and CEO of the King Hussein Cancer Center ( https://www.khcc.jo/en ) in Amman, Jordan, where he led the development of the largest cancer center in the MENA region. He also served as the director of the Georgia Cancer Center, the state cancer center, at Augusta University. He is currently a biomedical scholar and holds a professorship at Georgetown University Medical School.Dr. Khleif also served as a Special Assistant to the Commissioner of the FDA, leading the FDA's Critical Path Initiative for Oncology. He is a member of the board of directors of Ayala Pharmaceuticals and Emerald Biopharmaceutics, and served as a member of the scientific advisory board of more than 20 biotechnology and pharmaceutical companies.Dr. Khleif is an international KOL in immunology and immunotherapy. He has served on many national committees, including the Scientific Advisory Board of the Biden Cancer Initiative, as chair of the Immunotherapy Committee for NRG, and as a member of the NCI Cooperative Group. He currently serves as an advisor for the Parker Institute for Cancer Immunotherapy. Dr. Khleif is an editor of three books, the author of hundreds of peer-reviewed scientific research articles, and a prolific inventor with more than 150 patents issued or pending in the field of immunology and immunotherapy.Dr. Khleif received his medical degree at the University of Jordan, Amman Jordan. He completed his residency in Internal Medicine at the Medical College of Ohio and his fellowship in Medical Oncology at the National Cancer Institute (NCI) in Bethesda, Maryland.#SamirKhleif #Georgiamune #Immunotherapy #KingHusseinCancerCenter #CriticalPathInitiative #FDA #Tregs #RegulatoryTCells #Cancer #Oncology #CheckpointInhibitors #ImmuneEscapeMechanisms #DualFunctioningAntibody #Autoimmune #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast #STEM #Innovation #Science #Technology #ResearchSupport the show

Dr. Michael Biamonte is the founder of the Biamonte Center for Clinical Nutrition. He is a co-creator of BioCybernetics, which is an unprecedented computer software program that is able to study blood work, mineral tests and many other lab tests to determine exactly where your body is imbalanced, initially designed for aerospace purposes.  As a practitioner for over 30 years, Dr Biamonte is dedicated to improving the lives of his patients and helping them get back to living.  He holds a Doctorate of Nutripathy and is a New York State certified Clinical Nutritionist. He is a professional member of the International and American Association of Clinical Nutritionists, The American College of Nutrition and is a member of the Scientific Advisory Board for the Clinical Nutrition Certification Board. He is listed in “The Directory of Distinguished Americans'' for his research in Nutrition and Physiology.   FREE BOOK:   Send an email to: drb@health-truth.com    request: The Candida Chronicles & 5 Phase Treatment     Contact:   Web  www.health-truth.com   Facebook - https://www.facebook.com/The-Biamonte-Center-241435772676317/   YouTube - https://www.youtube.com/channel/UCiss7csT6pBnPAyeNA5AbDQ

SHINING WITH ADHD #195: Why ADHD Sleep Problems Happen and How You Can Help: Practical Strategies from A Sleep ExpertThe Childhood Collective4/30/2025SUMMARYIs your child dealing with ADHD sleep problems? Many children with ADHD have trouble falling asleep, staying asleep, or waking too early. The truth is, it can be incredibly difficult for the entire family. Today, we have the honor of talking with Dr. Roberto Olivardia, a leading expert on ADHD and sleep, to uncover why these challenges happen—and, more importantly, how you can help. Effortlessly combining the science of sleep with humor and creative ideas, Dr. Olivardia shares innovative sleep strategies for ADHD that can make nights (and mornings!) easier for you. MEET DR. OLIVARDIADr. Roberto Olivardia is a Clinical Psychologist, Clinical Associate at McLean Hospital and Lecturer in the Department of Psychiatry at Harvard Medical School. He is on the Scientific Advisory Board for ADDitude, as well as sits on the Professional Advisory Boards for Children and Adults with ADHD (CHADD), the Attention Deficit Disorder Association (ADDA), and is a Featured Expert for Understood. He presents at many conferences, podcasts and webinars around the country. LINKS + RESOURCESEpisode #195 TranscriptContact Dr. OlivaridaThe Childhood Collective InstagramHave a question or want to share some thoughts? Shoot us an email at hello@thechildhoodcollective.comMentioned in this episode:Shining at SchoolShining at School is a video-based course that will teach you how to help your child with ADHD go from surviving to thriving at school for elementary and middle schoolers. On your own time. At your own pace. Use the code PODCAST for 10% off!Shining at School CourseHungryrootHungryroot offers “good-for-you groceries and simple recipes.” We have loved having one less thing to worry about when it comes to raising kids. For 40% off your first box, click the link below and use CHILDHOOD40 in all caps to get the discount.HungryrootZenimalWe love the Zenimal. It's amazing for kids who are feeling anxious or need a little help calming their busy body before bed. The best part? Each meditation ends with the most beautiful message: “You're a good kid!” Use our code: TCC for a 15% off discount.Zenimal

In this special rerun episode of The Poultry Nutrition Blackbelt Podcast, we revisit our conversation with Dr. Michael Rothrock Jr., from USDA-ARS, who discusses his work in pre-harvest food safety and its impact on poultry systems. He shares insights into microbial ecology, soy-free diets, and the critical role of the microbiome in food safety and bird health. Gain valuable knowledge on how feed composition and environmental factors influence poultry production. Listen now on all major platforms!"The whole picture starts with the ecology; it influences everything, even feed additive effectiveness."Meet the guest: Dr. Michael Rothrock Jr. is a USDA Research Microbiologist with over 19 years of experience. He specializes in molecular microbial ecology and food safety microbiology. With a Ph.D. in Microbiology from Arizona State University, Dr. Rothrock is on the Scientific Advisory Board for the OECD - Cooperative Research Program.What you'll learn:(00:00) Highlight(01:34) Introduction(02:44) Pre-harvest food safety explained(04:12) Insights on pastured systems(05:07) Diets and microbiomes(07:06) Feed ingredients and pathogens(10:24) Role of microbial ecology(14:04) Closing thoughtsThe Poultry Nutrition Blackbelt Podcast is trusted and supported by innovative companies like:* Kemin* Kerry- Poultry Science Association- Barentz- Zinpro- Anitox- BASF

Today, I have the pleasure of speaking with Volker Then, an independent Senior Impact Analyst who is launching a start-up company on Comprehensive Impact Measurement together with a coalition of impact partners. From 2022 to 2024, Volker was Founding Chief Executive Officer and Member of the Executive Board of Fondazione AIS (Advancing Impact and Sustainability) in Bologna. Earlier in his career, Volker was Executive Director of the Centre for Social Investment at Heidelberg University for 15 years and also served as Director Philanthropy and Foundations at the Bertelsmann Foundation. He is a former member of the Scientific Advisory Board of the OECD's Global Action “Social and Solidarity Economy” and served on the National Advisory Board of the G7-Social Impact Investment Task Force. Impact is a big word nowadays – maybe even a buzzword – and people in our space are using it broadly and frequently. But it's not clear that everyone has a clear shared definition of the term. Volker provides his definition of “impact”, especially as it relates to enterprise families and the objectives they set for themselves with regard to fulfilling the purpose of their wealth and their family capital. One of the greatest challenges, and opportunities, in the world of impact is the measurement of the effectiveness and outcomes of impact initiatives. Volker talks about the latest thinking and work that is being done in this area, especially the thought leadership and development he has been spearheading in his prior role at Fondazione AIS and now in his current venture. Volker offers his tips and suggestions for enterprise families who are just starting or are early in their impact journey, focusing on what he recommends they do to get better educated and equipped to realize their impact ambitions. He then turns to enterprise families who are more advanced and have a developed impact framework and strategy, sharing his advice on what they can do to further the reach and consequence of their impact programs and strategies. Don't miss this enlightening conversation with one of the foremost thought leaders in the realm of impact definition and measurement.

What's the difference between a Scientific Advisory Board and a Board of Directors—and why does it matter for your startup's success? In this episode, hosts Elaine Hamm, PhD, and James Zanewicz, JD, LLM, RTTP, break down the critical roles that Scientific Advisory Boards (SABs) and Boards of Directors (BODs) play in the biotech startup world. With candid insights, real-world stories, and practical advice, this episode gives you a front-row seat to the boardroom—and why who you put there can make or break your company. In this episode, you'll discover: The strategic differences between SABs and BODs—and how to know when to build each one. How to identify the right board members, what to avoid, and when to grow your board. Common pitfalls (like yes-men and micromanagers) and how to build a board culture rooted in trust, transparency, and mission alignment. Whether you're forming your first board or thinking about your next funding round, tune in to learn how to build boards that work for your company, not against it. Links: Connect with Elaine Hamm, PhD, and James Zanewicz, JD, LLM, RTTP, and learn about Tulane Medicine Business Development and the School of Medicine. Check out Osage University Partners and connect with Kirsten Leute, MBA. Listen to our previous episode with Kirsten Leute on The Equalize Program. Check out BIO on the BAYOU and make plans to attend October 28 & 29, 2025. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Hi friends! I'm so excited to have Dr. Michael Biamonte on the show today and we're talking all about Candida.   - What is Candida and why do traditional treatments fail? - How do parasites contribute to Candida? - His protocol for rebalancing the body with Candida overgrowth - His tips for being Healthy in Real Life  and so.much.more. Here's more info about Dr. Biamonte: Michael Biamonte is the founder of the Biamonte Center for Clinical Nutrition. He is a co-creator of BioCybernetics, which is an unprecedented computer software program that is able to study blood work, mineral tests and many other lab tests to determine exactly where your body is imbalanced initially designed for aerospace purposes. As a practitioner for over 30 years, he is dedicated to improving the lives of his patients and helping them get back to living. He holds a Doctorate of Nutripathy and is a New York State certified Clinical Nutritionist. He is a professional member of the International and American Association of Clinical Nutritionists, The American College of Nutrition and is a member of the Scientific Advisory Board for the Clinical Nutrition Certification Board. He is listed in “The Directory of Distinguished Americans'' for his research in Nutrition and Physiology. You can check out his website, connect with him on Instagram, and read his book here.  Partners: The Lifewave X39 patches have been a gamechanger for my energy; the Pilot is obsessed, too! Check them out here.  Check out my new favorite red light device here, and use the code FITNESSISTA for a huge discount.  I've been using Nutrisense on and off for a couple of years now. I love being able to see how my blood sugar responds to my diet and habits, and run experiments. You can try out Nutrisense here and use GINA50 for $50 off. If any of my fellow health professional friends are looking for another way to help their clients, I highly recommend IHP. You can also use this information to heal yourself and then go one to heal others, which I think is a beautiful mission. You can absolutely join if you don't currently work in the health or fitness industry; many IHPs don't begin on this path. They're friends who are passionate to learn more about health and wellness, and want to share this information with those they love. You can do this as a passion, or start an entirely new career. You can use my referral link here and the code FITNESSISTA for up to $250 off the Integrative Health Practitioner program. I highly recommend it! You can check out my review IHP Level 1 here and my review of Level 2 here. Thank you so much for listening and for all of your support with the podcast! Please be sure to subscribe, and leave a rating or review if you enjoyed this episode. If you leave a rating, head to this page and you'll get a little “thank you” gift from me to you. 

The amount of time children and adolescents spend with a screen is absolutely stunning. Lots of people, including parents, health leaders, educators, elected leaders from both parties I might mention, and even children themselves, are highly concerned and are discussing what might be done about all this. I'm delighted to begin this series of podcasts on children and screen time. Today we're welcoming two very special guests who can talk about this topic in general, and especially about what's being done to protect children and adolescents. Several podcasts will follow this one that deal with food and nutrition in particular. Our first guest, Kris Perry, is Executive Director of Children and Screens, an organization devoted to protecting children. In the digital world by addressing media's impact on child development, communicating state-of-the-art information, and working with policymakers. Prior to joining children in Screens, Kris was senior advisor of the Governor of California and Deputy Secretary of the California Health and Human Services Agency. Our other guest, Dr. Dimitri Christakis is a professor of pediatrics at the University of Washington School of Medicine, and director of the Center for Child Health Behavior and Development at Seattle Children's. He's also editor-in-chief of JAMA Pediatrics and both Chief Scientific Officer and Chair of the Scientific Advisory Board of Children and Screens. He's also the co-editor of a new book that I'm very excited to discuss. Interview Summary Download The Handbook of Children and Screens: https://link.springer.com/book/10.1007/978-3-031-69362-5 Kris, let's start with you. Could you set the stage and give us some sense of how much time children spend in front of screens, children and adolescents, and what devices are being used and what kind of trends are you seeing? Yes, I'd be happy to. I had better news for your listeners, but as you might imagine, since the advent of the smartphone and social media, the youth digital media use has been increasing each year. Especially as children get older and have increasing demands on their time to use screens. But let's just start at the beginning of the lifespan and talk about kids under the age of two who shockingly are spending as much as two hours a day on screens. Most spend about 50 minutes, but there's a significant chunk spending up to two hours. And that rises to three or three to five hours in childhood. And eventually in adolescence, approximately eight and a half hours a day our adolescents are spending online. Also wanted to talk a little bit about middle childhood children, six to 12 years of age. 70% of them already have a social media account, and we all know social media wasn't designed for children. And there are restrictions on children under 13 using them, and yet children six to 12 most have an account already. Over half of four-year-olds have a tablet and two thirds of children have their own device by the age of eight; and 90% of teens. This probably won't be surprising, and yet we should really think about what this means; that 90% of teens are using YouTube, 60% are on TikTok and Instagram, and 55% use Snapchat. I'll stop by ending on a really alarming statistic. Oh my, there's more? There's more. I know it! I told you. I'll be the bearer of bad news so that we can talk about solutions later. But, children are checking their devices as often as 300 times per day. 300 times. 300 times per day, and we're talking about screen time right now. And we know that when you're using time to be on screens, you are not doing something else. And we know that childhood is full of challenges and skill building and mastery that requires repetition and tenacity and grit and effort. And the more children are on their screens, whether it's social media or other entertainment, they're not doing one of these other critical child development tasks. That's pretty amazing. And the fact that the older kids are spending more time on before a screen than they are in school is pretty alarming. And the younger, the really youngest kids, that's especially alarming. So, Dimitri, why should we fret about this? And I realize that fret is kind of a mild word here. Maybe all I'll panic would be better. But what are some of the major concerns? Well, I don't think panic is ever the right reaction, but the numbers Kris conveyed, you know, I think do paint a, let's say, concerning story. You know, the simple reality is that there's only so much time in a day. And if you think about it, teenagers in particular should sleep for eight to 10 hours a day at a minimum. They really should be in school six and a half, seven hours a day. And then when you add the numbers, Kris conveyed, you realize that something's giving because there isn't enough time left to spend eight and a half hours a day. The two things at a minimum that are giving are sleep. Kids are losing sleep to be on screens. And I'm sorry to say that they're losing school while they're on screens. We just published a paper that used passive sensing to see where and when children are on their screens. And found that the typical child in the United States spends an hour and a half during the school day on their device. And it's not, before any of your guests ask, on Wikipedia or Encyclopedia Britannica. It's on the usual suspects of social media, TikTok, etc. So, you know, we talk about displacement, and I think it's pretty obvious what's being displaced during school hours. Its time focused on learning if it's in the classroom, and time focused on being authentically present in real time and space if it's during recess. School hours are precious in that way, and I think it is concerning that they're spending that much time in school. And I told you the median. Of course, some kids are above that, a significant half of them are above it. And at the high end, they're spending 30 to 40% of school time on screens. Now, some schools have enacted policies. They don't typically enforce them very well. One of the things that drives me nuts, Kelly, is that as an academic, you know we love to argue amongst ourselves and hem and haw. And this issue about whether or not there's such a phenomenon as digital addiction is still being hotly debated. Honestly, the only behavioral addiction that's being seriously considered at this point is gaming disorder. The DSM-5 didn't consider gaming, considered it, but didn't include, it said it needed further study in 2013. In 2022, the WHO did include gaming disorder as an ICD-11 diagnosis. But just as further evidence how slow science is compared to technology., I mean gaming, while it's still an entity, represents a small fraction of most people's screen time. And the numbers that Kris conveyed, a small fraction of that for some on average was gaming. For some people, it's their screen use of choice, but for many, it's social media. YouTube, although I consider YouTube to be a social media, etc. And at the high end when you hear the numbers Kris conveyed in my mind that's a behavioral addiction any way you define it. Well, and if you think about things that we all agree are addictive, like nicotine and alcohol and heroin, people aren't doing it 300 times a day. So it's really pretty remarkable. And that's exactly right. One of the salient criteria for those addictions is that it's interfering with activities of daily living. Well, you can't be on a screen for nine hours a day when you're supposed to be asleep for 10 and at school for six without interfering with activities of day. The math isn't there. And things like being physically active and going out and playing. That's right. It doesn't add up. So, you don't need the DSM-5. You don't need a psychiatrist. You need a mathematician to tell you that there's too much time on this thing. Alright, so Kris, talk to us if you will, about the Children and Screens organization. I have a lot of respect for the organization and its work. Tell us how it got started and what its objectives are. Well, it's so great to be on this show with you and get to see you in your day job, Kelly. Because you've been an advisor, like Dimitri, to the institute almost since its inception, which is in 2013. As you know, our founder, Dr. Pamela Hurst-Della Pietra, really became concerned as a parent about the way digital media was impacting her children and sought out some answers. Well, what does this mean? Why is this happening? What should I do? And found out that this, of course, is 2013, this is a long time ago. There wasn't that much research yet. And it was multidisciplinary. In other words, there might be a study among neuroscientists or developmental psychologists, even ophthalmologists. But there really hadn't been, yet, a concerted effort to bring these different disciplines and the research together to try to answer some of these hard questions about the impact on kids. And lo and behold, here we are, almost 13 years since the advent of the smartphone and social media. And there is an astounding amount of research across disciplines. So, what we do at the institute is we try to translate it as fast as we can and make it actionable for parents, providers, and policy makers. And we do that through our Ask the Experts webinar series where we bring the experts themselves directly to our audience to talk about these impacts and answer questions. We also create printables, you might say, like tip sheets and Research at a Glance Digest, and newsletters and FAQs and we've upgraded our website to make it very navigable for parents of kids of all ages. I even started my own podcast this year, which has been really fun. Dimitri was my first guest, so it's great to see him here. And we have convenings. We're having our third Digital Media Developing Mind Scientific Congress this summer where the experts come together in person to discuss issues. And we really try to focus them on advancing research and supporting it, translating it, and positioning the issue as a policy priority. We'll be in Washington, DC where we know lawmakers are grappling with the impact of digital media on child development, how to make online, products safer for kids and protect their data. The Institute is in the middle of all of this, trying to facilitate more discussion, more results and more support for parents primarily. Kris, a couple of things occur to me. One is that the breadth of work you do is really very impressive because you're not only having very hands-on kind of in the real world ex advice for parents on how to navigate this world, but you have advice for and helpful resources for policy makers and for researchers and people. It's really quite an impressive breadth of work. The other thing that occurred to me is that I don't think you and I would have any podcast career at all if it hadn't been for Dimitri helping us out. So thanks Dimitri. Yeah. So, let me ask you, Dimitri, so I know that both you and Kris are committed to an evidence-based approach to making policy. Yeah. But technology advances way more quickly than scientists can evaluate it. Much less come up with policies to deal with it. And by the time research gets funded, completed, published, you're on to eight new levels of technology. So how does one handle this fundamental problem of pace? It's a really good question. I mean, I can tell you that we should at a minimum learn from the mistakes we've made in the past. And, you know, one of the most critical, frankly, that most people don't really understand is that we talk about the age at which children get social media accounts in this country. Kris pointed out that actually pre-teens routinely have social media accounts. Social media companies do very little to age gate. They're trying to do more now, but even the age at which we've accepted it is being normative is 13. Few people know where that comes from. That doesn't come from talking to pediatricians, psychologists, parents about what age is the appropriate age. It comes entirely from COPPA (Children's Online Privacy Protection Act), which basically was the original privacy act that said that before the age of 13, companies could not collect data from children. So, because these companies were interested in collecting data, they set the age at 13 so as to not have any constraints on the data they collected. Well, that's not even common sense-based policy, let alone evidence-based policy. And it's never been revisited since. It's very troubling to me. And as things move forward, I think we have to learn from those mistakes. Medicine has a maxim which is do no harm. We use that phrase a lot and I think it's a good one in this case. I think it's a particularly good one as we see the new technologies emerging around artificial intelligence. And you know, again, like any new technology, it has incredible upside. We made the mistake and we're still paying for it, about not appreciating the downsides of social network sites, and frankly, the internet in general. And I would hope we put guardrails in place now. And if you will apply the same standard we apply to other non-technology based products. You can't introduce a new pharmaceutical to anybody, let alone to children, until you show it's safe and effective. You can't bring toys to the world that are dangerous. Why do we have more safety precautions around toys than we do around websites for children? You know, a lot of it involves changing defaults, doesn't it? Because if the default is that government or somebody out there has to prove that something is harmful before it gets taken away. That changes everything then if you began at a different point where these companies have to prove that these things are safe. Correct. Or they're permitted. Then the companies would find workarounds and they would play games with that too, but at least that would help some. Well, it would help some. And at least we'd be philosophically in the right place. By the way, Kris didn't say it, so I'll say it. You know, the mission of Children and Screens, lest we sound like Luddites here, is not get kids away from technology. Take away their smartphones. We all recognize that technology is here to stay. I think all of us appreciate the incredible upside that it brings to children's lives. The mission of Children and Screens is to help children lead healthy lives in a digital world. And part of the reason she and I often talk about the concerns we have is because the pros make the case for themselves. I mean, you know, no one needs to come here and tell you how amazing it is that you could Google something or that you could get somewhere with GPS. I mean, we know it's amazing and we all rely on it. And none of us are ever talking about getting rid of that stuff. That makes good sense. It's like, you know, children benefit from the fact that they can get around with their parents in the automobile. But you want to have car seats in there to protect them. Exactly. And that's exactly right. There needs to be assurances of safety and they're none. I mean, they're really virtually none. The age getting is a joke. And even if we accept it as effective, the age set of 13 is too young, in my opinion. We started this conversation talking about these medias being addictive, I believe they're addictive. There are legitimate academics that will debate me on that, and I'm happy to join that debate. But as I said before, it's a tough argument to win when people spending upwards of 10 to 16 hours a day doing it. I don't know what you call that besides addictive. We can argue about what percentage are doing that, but nevertheless, once you accept something as addictive, for other addictive things we immediately age gate it above 18 or 21, right? Mm-hmm. We don't believe that the teenagers have the ability to regulate their alcohol or tobacco or gambling, all of which we accept are addictive. In fact, in the case of alcohol, we raised the age from 18 to 21 because we thought even 18-year-olds weren't able to do it. And yet somehow for this behavior, we think of it as just so different that it doesn't require greater cognitive capacity. And I don't believe that. Yeah, very good point. Kris, let me ask you a question about how you and your colleagues at Children and Screens set priorities because there are a lot of things that one could potentially worry about as outcomes. There's violence that kids see on social media. There's cognitive and brain development, social developments, social interactions, and bullying. Mental health, body image, diet, all these things are out there. How do you decide what to work on? Well, we try to work on all of it. And in fact, we've built up a fair amount of expertise and resources around almost 25 different topics. And we also understand that, you know, childhood is a long period of time. Birth to 18, birth to 21, birth to 25, depending on who you talk to. So, we're able to take those 25 topics and also provide deeper, you might say, resources that address the different stages of development. We're really trying to do as much as we can. What's been interesting over these last few years is trying to figure out when to be reactive, when to be proactive. And by being proactive, we go out looking for the research, translating it, digesting it, and creating materials with it that we think are really accessible and actionable. At the same time, as Dimitri points out, there are policy windows and there are opportunities that present themselves that you have to react to. If you just only talk about what you want to talk about to each other you're missing some of these external opportunities to inform policy and policy makers. Help influence the way that parents and providers are talking about the issue. Framing it in such a way that engages youth and makes them want what we want for them. We're really excited by increasing opportunities to partner in coalitions with others that care about kids and teachers and nurses and doctors. But we also are speaking directly to leaders in states and school districts at the federal level, at the local level. You would be, I'm sure, not surprised to hear that we are contacted every day by groups that support parents and families. Asking for resources, asking for support, because they're seeing the impact now over many years on their children, their development. Their academic ability. Their cognitive and analytical ability. Their social emotional ability. Their ability to pay attention to tasks that we all know are critical in building that foundation for essentially, you know, future success. The Institute is being pulled in many directions. Ee try really hard to be strategic about what are people asking us for? What does the research say and how can we get that to them as quickly as possible? Dimitri - Can I add to that? You know, I want to emphasize that the concern around the effects of screen use on children's lives is shared by parents on both sides of the aisle. 75% of parents are concerned about the impact of screens on their children's lives. 35% of teenagers are concerned about their dependents on screens and that it has a negative effect on their lives. Actually by some studies, some surveys, even more than 35 to 50% of teenagers are concerned. And both sides of the political aisle agree in large part of this. And Kris and Kelly, you guys are the policy wonks, you can speak more to that. So it's a serious indictment on us as grownups and as a society that we have not done more to deliver on this issue. Why? When there's bipartisan agreement amongst many policymakers. This is not a political [00:22:00] issue to speak of and there is widespread concern on the part of parents and even teenagers. Why is nothing happening? Well, one has to look no further than where the money is. And that's a problem. I mean, that's a serious indictment on our political system when we can't deliver something that is needed and basically wanted by everybody but the industry itself. We'll come back and talk in a few moments about the policy issues and where industry gets involved here. But let me take just a bit of a detour from that and talk about the book that I mentioned earlier, because I think it's such a valuable resource. Now, when I mention the name of this book I'm urging our listeners to write this down or to remember it because you can get the book at no cost. And I'll come back, Kris, and explain what made that possible and why the decision was to make this an open access book. But Dimitri, let's begin with you. So you, along with Lauren Hale, edited this book that's entitled, The Handbook of Children and Screens: Digital Media Development and Wellbeing From Birth Through Adolescence. I think it's an extraordinary piece of work, but tell, tell us about the book.  It was an extraordinary undertaking. There's I think 178 or 180 authors. Literally, it's a who's who of experts in children and media research in all disciplines. It represents pediatrics, psychiatry, psychology, communications experts, demography, lawyers, neuroscientists. I don't know who I'm forgetting. Every single discipline is represented. Leading scientists in all of those areas. Virtually every topic that someone might be of interest to people. And we deliberately made the chapters short and easily accessible. So, it is, I think, a great resource for the constituents we serve. For teachers, for parents, for researchers, for policymakers. And it is free. The hardest part of it, to be honest, as an editor, was getting peer reviewers because unfortunately, every expert was conflicted since they all had an article in it. But it was a long time coming. And again, this was really the brainchild of Pam (Pamela Hurst-Della Pietra) and we're grateful to have brought it along. So, you go all the way from the neuroscience, how children's brains are reacting to this, all the way out there into the public policy and legal arena about what can be done about it. And then kind of everything in between. It's remarkable how much the book covers. It's almost a thousand pages. I mean, it is a tome to be sure. And don't forget to mention, Dimitri, we aren't even two months post publication, and we have 1.6 million views of the document, despite its gargantuan size. I think that is really a tribute to experts like you and others that have really studied this issue and can speak directly to its impacts. It's been great to see the success so far. You know, not a small number of those views is from me logging on. And then a million from me and then we got there. So, it is free because it's online and you can download it. You can also order a hard copy for I think, $60, but I'm not sure why you would do that if you can download it for free. But it's up to you. So, Kris, it's unusual for a book like this to be made open access and free to the general public. What made that possible and why was that so important? We want the maximum number of people to use it and treat it like the premier resource that it is. And the only way you can really do that is to fund it to be open access and find a publisher that does open access publishing, which we did with Springer. I mean, most journal articles are behind a paywall and publishers do require you to purchase either a subscription or the document itself to download it or order it. And we just really wanted maximum access. So, we funded it to be published in that way. And I think honestly, it helped us even sort of create it in the first place. People want to be a part of something that has that level of access and is available so widely. So, I think it was a kind of mutually beneficial. It gets more people to read it, but it got more people to write for it too, I think. Right, Dimitri? Dimitri - I agree. I mean, you know, the numbers 1.6 million are extraordinary. I mean, Kelly, you've been internal editor. I mean, as a editor of JAMA Pediatrics, if an article gets 70,000 views, it's in our top 1%, you know, 200,000 views is 0.01%. 1.6 million in growing is really extraordinary. And that's about the number of people that read my articles. 1.6. And of course, they're not all scientists. I mean, many of them are parents and maybe are policy makers, but that's Kris's point, you know. The moment anyone hits a paywall, even if it's a dollar or two, they're going to walk away. It's great to see it get so much traction. Alright, so again, for our listeners, the title of the book is The Handbook of Children and Screens. And it's really a terrific resource. Alright, so let's turn our attention to a really important matter. And we've sort of touched on this, but who's in charge of protecting our children? You know, Dimitri at the end of the day help survey this landscape for us. I mean, is it congress, is it the administrative branch of government? What role do the courts play? Are there legal actors taking meaningful action? What's being done does it come anywhere near, meeting the need. Tell us about what that landscape is like? Well, there isn't adequate protections for children. And we talked a little bit about that earlier. There's been an enormous loophole, unfortunately, created by Congress when they added the Section 230 to the Communications Decency Act in 1996. And that was put in place essentially to provide protections for internet companies. And it basically said that they should be treated like bookstores and not publishers. That they weren't responsible for content they were just conveying it. And what that means, in effect, was that the companies had sort of carte blanche to do whatever they want. And they've used that very effectively, legally, to argue that any restriction, any culpability on their part, is protected by that Act. That they're exonified for any ill that occurs as a result of their product. The only exception that's been made of it, to date, was around sex trafficking on back page, if anyone remembers that. But other than that, social media sites and internet sites in general have been able to say that they're not liable for anything that's done. And I think that was a huge mistake that was made. It needs to be rectified. It's being challenged in the courts presently. My own belief is that, and I'm not speaking as a lawyer, is that when that law was passed, it was under the assumption as I said, that they were just conveying information. No one at the time foresaw the development of algorithms that would feed the information. It's really not a bookstore when you are making recommendations. Once you start recommending things, I think you're no longer merely a purveyor of product. You're actually pushing it. So, Kris, tell us about the Children and Screens and the role the organization plays in this space. And how do you deal with policy and is it possible to be bipartisan? Yeah, I mean, it's essential. There's no way to get anything done, anywhere on these policy matters at a population level without working in a bipartisan or non-partisan manner, which is what we've always done. And it's easy to do that when you're following the science, not ideology. And you're putting the science first and you're creating resources and tools and support for those mostly staffers, honestly, that are trying to help their bosses get smarter and better at talking about these issues as they evolve and become more complicated over time. It takes more effort to staff a lawmaker on this front. And they're very anxious to learn and understand because they're meeting with parents of children who have been harmed. Or frankly didn't even survive their childhood because of the social media platform. There's great urgency on the part of policymakers. We've heard everything from school phone bans to outright social media bans proposed as policies. And one thing I like to come back to is it's one thing to want to take action and make your best guess at what would have the best impact. But it's another thing to study whether or not that policy actually achieved its result. And it's a part of this that by staying bipartisan, nonpartisan allows us to say, 'Hey lawmaker, if you're able to get that to happen, we'd really like to come in and help study whether or not your idea actually achieves the results that you wanted, or if it needs to be adjusted or amended over time.' Fantastic. That's so important to be doing that work, and I'm delighted the organization is doing it. Let me ask a question here. If you think about some of the areas of public health that I've been following, like tobacco, for example. Opioids more recently. Vaping products. And in the case of my own particular work food policy. The administrative legislative branches of government have been almost completely ineffective. If I think about food policy over the years, relatively little has been accomplished. Even though lots of people have worked really hard on it. Same thing happened with tobacco for many years. Opioids, same thing.  And it's until you get the third branch of government involved, the judiciary, and you start suing the actors who were causing the harm do you get much action. Not only do the lawsuits seem to have an effect, but they soften the ground for legislative things that then can occur because public opinion has changed. And then those things help make a difference as well. What do you think about that kind of issue in this space?  I think you're exactly right. I mean, I think the failure of our legislative branch to enact policy leaves us with very few options at this point anyway, except to try to pursue it through the judiciary. There are challenges there. First and foremost, it's a big and well-funded industry, not unlike tobacco or big food, as you mentioned and there's this Section 230 that's given them kind of blanket immunity to date. But there are many, many very large pending cases in several jurisdictions brought by individuals, brought by school districts, brought by states. And those, at least provisionally have gotten further than prior cases have with which have been thrown out based on Section 230. So, we'll see what happens with that litigation. But right now, my guess is it's the best chance we have to set some guardrails. And I think there are plenty of guardrails that could be set. Everything that these companies have done to make their products addictive can be undone. Can be made protective. The tobacco company deliberately designed their products to be addictive. While they tried to make the claims that they were less addictive, you know. They made light cigarettes that had holes in the filter so that it would diffuse the carbon and nicotine, but people quickly learned they could cover those up with their fingers and think they were smoking light cigarettes, and smoke more of them. There's a lot of things that can be done in this space to undesign the problematic nature of the products. And quite apart from the financial settlements, which will get companies attention, I hope that that's part of any settlement if it gets that far. It'll be interesting to see where those go. And, also historically, one important part of these lawsuits is what gets turned up in discovery. And what sort of intent the companies have and how much do they know about harms. And how much do they know about addiction and things like that. And how they might have proceeded in the face of that information that then doesn't get disclosed to the public. In any event, we'll see where that goes. Dimitri, what about the argument that responsibility resides with parents. It's up to parents to protect their kids from this, and government doesn't need to be involved. I've never understood that argument. I mean parents obviously are children's most important safeguard, but as a society, we enact policies and laws to assist parents in that. I mean to me, if I made the argument, well, why, why do we have minimum ages of drinking. It's parents' job to make sure their kids don't drink. How would that possibly play out? Look, it's hard enough as a parent anyway, because kids do get around these laws. But we still have them and it's a lot easier as a parent. I think most parents would agree their life's made easier by minimum age restrictions on certain things. We have seatbelt laws. I mean, why do we have seatbelt laws? Why don't we just tell its parents' job to make sure their kids buckle up? The truth is its society and parents working hand in hand to try and keep children safe. And I think it also helps parents to be able to say that there are laws around this, and I expect you to follow the laws. So, I don't think it's an either or. Okay, well, I think that's a very good way to frame it. There are many, many precedents where we protect children. And why not do it here too? So let me end with a question I'd like to ask both of you. So, in this sea of concerns that we've discussed, is there a reason for optimism? And Kris, let me start, start with you. What do you think? Absolutely. I think the young people I've met that are leading among their peers are incredibly impressive and are armed with the research and their energy and their own lived experience in ways that are very compelling. At the same time, I think the vast amount of research that has now been compiled and translated and acted upon, whether in courtrooms or in state houses, it's becoming more, and we're all getting more steeped and aware of more nuanced information. And finally, I would just say, there is a tipping point. We are reaching as a society, adults and kids alike, we are reaching a tipping point where we can't withstand the pressure of technology in every aspect, every corner of our day, our life. And we want relief. We deserve relief. And I think that's what's going to take us over the finish line. Good. Well, I'm glad to hear those optimistic notes. Dimitri, what about you? I can find reasons to be optimistic. I mean, look, the reality is that technologies have enriched our lives in many ways. And I think if we put guardrails in place, we can make sure that future ones do even better. I have a piece coming out in JAMA Pediatrics around the use of AI, which people are very concerned about, I think rightly. But specifically, about the use of AI and people with intellectual developmental disabilities, making the use case, that there are ways in which it could be extremely beneficial to that population. A population I care deeply about in my role as the Chief Health Officer at Special Olympics International. And in particular, let's say in terms of the doctor patient interaction where it could facilitate their communication with their provider, and it could also help the provider better communicate with them. Look, that use case isn't going to be a priority for the purveyors of artificial intelligence. It's a small, non-lucrative use of a technology. But it's a good one. And if we created the right incentives and put in the right guardrails, we could find many other ways that technology can serve the needs of all of us going forward. I think the problem is that we've tended to be reactive rather than proactive. And to not start with the do no harm first premise, particularly when it comes to children. AI is another example of that where I hope we don't make the same mistake we made with social media. Bios Kris Perry is the executive director of the Children and Screens Institute. Kris most recently served as Senior Advisor to Governor Gavin Newsom of California and Deputy Secretary of the California Health and Human Services Agency where she led the development of the California Master Plan for Early Learning and Care and the expansion of access to high-quality early childhood programs. She led systems change efforts at the local, state and national levels in her roles as executive director of First 5 San Mateo, First 5 California and of the First Five Years Fund. Through it all, Perry has fought to protect children, improve and expand early learning programs, and increase investments in low-income children. Perry was instrumental in returning marriage equality to California after the landmark 2013 U.S. Supreme Court ruling Hollingsworth v. Perry, which she wrote about in her book Love on Trial (Roaring Forties Press, 2017). Dimitri Christakis, MD, MPH is the Children and Screens Institute's inaugural Chief Science Officer. He is also the George Adkins Professor at the University of Washington, Editor in Chief of JAMA Pediatrics, and the Chief Health Officer at Special Olympics International. Christakis is a leading expert on how media affects child health and development. He has published over 270 peer reviewed articles (h-index 101) including dozens of media-related studies and co-authored a groundbreaking book, The Elephant in the Living Room: Make Television Work for Your Kids. His work has been featured on Anderson Cooper 360, the Today Show, ABC, NBC, and CBS news as well as all major national newspapers. Christakis received his undergraduate degree at Yale University and his medical training at the University of Pennsylvania School of Medicine and completed his residency and Robert Wood Johnson Clinical Scholar Fellowship at the University of Washington School of Medicine. 

Roughly 80% of perimenopause and menopause symptoms are brain-derived. From mood swings to low-stress tolerance, insomnia, and more… are you taking care of your brain during this huge transition period in midlife?  It's no wonder one of the biggest concerns of women over 40 is their mental health. So, if you're experiencing anxiety, overwhelm, brain fog, and irritable mood, you're NOT alone.  That's why Dr. Drew Ramsey is joining me on the podcast today to share his expertise on mental health and teach you how to feel safe in your body and brain.  We talk about:  What the modern brain is, and what you can do for optimal brain health in today's world  Tackling obstacles when it comes to caring for your mental health Must-do habits for your brain that you can easily start ASAP And MORE Don't miss this episode– because with the right mental fitness, you'll start to feel like yourself again, and stay that way for good! Drew Ramsey, MD Dr. Drew Ramsey is a board-certified psychiatrist, author, and mental health advocate who founded the Brain Food Clinic– a digital mental health clinical practice. He's written several books that explore the connections between mental health and nutrition. He's also on the Advisory Board at Men's Health, the Editorial Board at Medscape Psychiatry, and the Scientific Advisory Board of the anti-stigma nonprofit Bring Change To Mind. IN THIS EPISODE Prioritizing mental health in our modern world  The science behind movement for mental health  The impact past traumas have on your stress response  Implementing mental fitness for the whole family  Overcoming common obstacles when improving mental fitness  The power of journaling for your mental health Practical steps for healing your brain and improving mental fitness QUOTES “I don't want mental fitness in any way to be oppressive. My idea is that it's inspirational because it feels good.” “I'm a big advocate of therapy, not just for symptom control and because you're struggling with mental health, but for mental fitness for this notion of an ongoing kind of maintenance and attention to your mind, your mental health, and your specific goals.” “This transition in the 40s, 50s, and 60s into the next chapters of life– being more intentional, being more clear about the challenges for each of us… I think it helps us have a little more grace and feel more oriented.” RESOURCES MENTIONED Get Dr. Ramsey's Book: Healing the Modern Brain Dr. Ramsey's Website Dr. Ramsey's Instagram RELATED EPISODES  594: What I Did This Past Year to Heal My Brain and Lower Systemic Inflammation 586: What You Can Do in Perimenopause to Optimize Your Energy, Resilience and Brain Power with Dr. Mariza #469: Six Powerful Ways to Keep Your Brain Young and Clear #476: How to Pivot in Perimenopause to Increase Energy, Metabolism and Brain Power

Anna is a Professor of Computer Science at Brown University. Her research spans many areas of advanced cryptography including with digital signatures, group signatures, blind signatures, e-cash and anonymous digital credentials. She was originally from Ukraine, and undertook her masters degree at MIT in 1999, and then went onto a PhD in 2002 in the areas of Signature Schemes and Applications to Cryptographic Protocol Design. She joined Brown University in 2002, and was made a full professor in 2013. She is a member of the board of directors at  the IACR, along with serving  on Scientific Advisory Board for the Board of Directors of the Electronic Privacy Information Center (EPIC). In 2024, she was awarded the Levchin Prize for a contribution entitled "For the Development of Anonymous Credentials".

Rare condition research is evolving, and patient communities are driving the breakthrough. In this special Rare Disease Day episode, we explore the challenges and opportunities shaping the future of rare condition therapies. From groundbreaking gene therapy trials to the power of patient-driven research, our guests discuss how collaboration between families, clinicians, researchers, and regulators is paving the way for faster diagnoses, equitable access to treatments, and innovative approaches like nucleic acid therapies and CRISPR gene editing. With insights from Myotubular Trust, we follow the journey of family-led patient communities and their impact on advancing gene therapy for myotubular myopathy - showcasing how lived experience is shaping the future of medicine. However, while patient-driven initiatives have led to incredible progress, not every family has the time, resources, or networks to lead these research efforts. Our guests discuss initiatives like the UK Platform for Nucleic Acid Therapies (UPNAT), which aims to streamline the development of innovative treatments and ensure equitable access for everyone impacted by rare conditions. Our host Dr Ana Lisa Tavares, Clinical lead for rare disease at Genomics England, is joined by Meriel McEntagart, Clinical lead for rare disease technologies at Genomics England, Anne Lennox, Founder and CEO of Myotubular Trust and Dr Carlo Rinaldi, Professor of Molecular and Translational Neuroscience at University of Oxford. "My dream is in 5 to 10 years time, an individual with a rare disease is identified in the clinic, perhaps even before symptoms have manifested. And at that exact time, the day of the diagnosis becomes also a day of hope, in a way, where immediately the researcher that sent the genetics lab flags that specific variant or specific mutations. We know exactly which is the best genetic therapy to go after." You can download the transcript, or read it below. Ana Lisa: Welcome to Behind the Genes.    [Music plays]  Anne: What we've understood is that the knowledge and experience of families and patients is even more vital than we've all been going on about for a long time. Because the issue of there being a liver complication in myotubular myopathy has been hiding in plain sight all this time, because if you asked any family, they would tell you, “Yes, my son has had the odd liver result.”  There were some very serious liver complications but everybody thought that was a minor issue, but if we are able to engage the people who live with the disease and the people who observe the disease at a much more fundamental level we may be able to see more about what these rare genes are doing.  [Music plays]  Ana Lisa: My name is Ana Lisa Tavares, I'm Clinical Lead for Rare Disease research at Genomics England and your host for this episode of Behind the Genes. Today I'm joined by Anne Lennox, Founder and CEO of the Myotubular Trust, Dr Meriel McEntagart, an NHS consultant and Clinical Lead for Rare Disease Technologies at Genomics England, and Dr Carlo Rinaldi, Professor of Molecular and Translational Neuroscience at the University of Oxford.    Today we'll be hearing about the importance of involving the patient community, particularly as new rare therapies are developed, and discussing the forward-facing work that's happening that could have potential to unlock novel treatments for many rare conditions.  If you enjoy today's episode we'd love your support. Please like, share and rate us on wherever you listen to your podcasts. Thank you so much for joining me today.  Please could you introduce yourselves.   Anne: I'm Anne Lennox, I'm one of the founders of the Myotubular Trust, a charity that raises research funds for and supports families affected by the rare genetic neuromuscular disorder myotubular myopathy.  Meriel: I'm Meriel McEntagart, I'm a consultant in clinical genetics in the NHS and I have a special interest in neurogenic and neuromuscular conditions.  Carlo: Hi, I'm Carlo Rinaldi, I'm Professor of Molecular and Translational Neuroscience at the University of Oxford. I'm a clinician scientist juggling my time between the clinic and the lab where we try to understand mechanisms of diseases to develop treatments for these conditions.  And I'm also here as a representative of the UK Platform for Nucleic Acid Therapies, UPNAT. Thanks for your invitation, I'm very pleased to be here.  Ana Lisa: Thank you. Meriel, I'd love you to tell us a bit about your work and how you met Anne, how did this story start?  Meriel: Thank you. Well prior to being a consultant in clinical genetics, I spent 2 years as a clinical research fellow in neuromuscular conditions, and as part of that training I worked on a project where the gene for myotubular myopathy had just been identified, and so there was a big international effort to try and come up with sort of a registry of all the genetic variants that had been found as well as all the clinical symptoms that the affected patients had, and then do kind of a correlation of the particular variant mutation with symptoms.   I worked when I was training to be a clinical geneticist because of my interest in neuromuscular conditions so when I eventually became a consultant at St George's Hospital I was actually interviewed by the Professor of Paediatrics and he knew Anne and her son, when Anne was looking for more information about the condition he suggested that perhaps I might be a good person for Anne to talk to.  Ana Lisa: Thank you. Interesting connections. Anne, can you tell us your story and how this led you to found the Myotubular Trust?  Anne: Yes, thanks Ana-Lisa.  Well, as many families will tell you when they're newly diagnosed with a rare disease, you go from knowing nothing about a condition to being one of the few deep experts in that condition because there are so few deep experts. So this happened to us in 2003 when our son, Tom, was born, and when he was born he was floppy and his Apgar scores, the scores they do on new-born babies, were pretty poor, and before long we knew that it was more than just momentary issues at birth.  And, cutting a very long story short, 5 weeks later he was diagnosed with this very rare neuromuscular genetic disorder that we didn't know we had in the family.  We were told that this was a very serious diagnosis.    At that time – more than 20 years ago – over 80% of those boys didn't make it to their first birthday and the stark statistic we had in our head a lot was that only 1% made it past the age of 10. And that has changed due to better ventilator and breathing equipment, etc, but at the time we expected that he might not make it to his first birthday.    We were very lucky, we had Tom longer than one year, we had him for nearly 4 years, 4 very lovely years where it was tough, but he was a really lovely member of our family.  Despite being really weak he managed to be incredibly cheeky and bossy, and he was a great little brother for his big sister. We were also very lucky that he was being looked after by Professor Francesco Muntoni, who is Head of the Paediatric Neuromuscular Service at Great Ormond Street. And, like Carlo, he is a clinical researcher and actually that I found to be amazing as a family member because you knew what was happening out there and Professor Muntoni, other than living with the reality day to day you want to know where things are going.    We began to realise that back then 20 years ago the more common rare neuromuscular diseases were finally beginning to get some fundamental research funds, like Duchenne, spinal muscular atrophy, and Professor Muntoni was very good at explaining to lay non-scientific parents like us that one day the technologies that would lead to a cure, that would re-engage proteins for other conditions and would translate down eventually into the possibility of replacing myotubularin, which is the protein not being produced or not being produced enough in myotubular myopathy. And then we began to understand actually what the barriers to that would be, that translating developments in more common, or let's say more prevalent conditions, would be hard to do without some translation research being done; you could not just not lag years behind, you could lag decades behind if you haven't done some other work.    So, I met Wendy Hughes, another mother, of a boy called Zak who was a few years older than Tom, and these were the days before social media, and it was amazing to be in contact with another family going through something similar and we had great conversations. But then they were also looked after by Professor Muntoni and we particularly began to develop the idea as 2 families that we might be able to raise some research funds towards this concept of keeping pace with the scientific developments.  And then we discovered there was no charity we could channel those funds through. Even the umbrella body for neuromuscular diseases who were covering 30 to 40 conditions, frankly, they just couldn't trickle their funding down into investing in every neuromuscular disease, and slowly but surely it dawned on us that if we did want to make that difference we were going to have to set up our own charity.   So that's what we eventually did and back in 2006, we founded what was actually the first charity in Europe dedicated to myotubular myopathy – luckily, more have come along since – and we were dedicated to raising research funding. In fact, it wasn't our goal to set up another charity but around that time, about a year in, we happened to go to a meeting where the Head of the MRC, the Medical Research Council, was giving a talk and he said that in the last few years the MRC had begun to really realise that they couldn't cure everything, that they couldn't cure the diseases that would be cured in the next millennium from a top down perspective. There had to be a trick, there had to be a bottom up as well, because that was the only way this was going to happen. And I have to say that that was a really reassuring moment in time for us to realise that we weren't just chasing pipe dreams and trying to do something impossible, that there was a role for us.    Ana Lisa: I think it would be really interesting for people to hear your story and the amazing set-up and fundraising that you've done, and at the same time it would be really good for us to reflect on how this isn't feasible for every patient and every family and how we're going to need to work cooperatively to move forwards with rare therapies.  Anne: When we explored the idea with Professor Muntoni and Meriel and others about setting up a charity one of the really reassuring things that Professor Muntoni got across to us was that this wasn't about raising the millions and millions it would take to fund clinical trials but the issue in the rare disease space was funding the proof of principle work, the work where you take a scientist's hypothesis and take it over the line, and the rarer the disease, the less places there are for a scientist to take those ideas. And the example he gave us was a piece of research like that might cost a hundred to a couple of hundred thousand, if you fund a piece of work like that and if it is successful, if the scientist's principle gets proven, then behind you it's much easier for the bigger muscle disease charities to also invest in it. It's harder for them to spread their money across all the very rare diseases hypothesis out there, but if you've helped a scientist get over the line they'll come in behind you and then they won't be the ones who fund the tens of millions that it takes to run a clinical trial.    If it's got potential, then that's where the commercial world comes in, and that's where the biotechs come in. So he'd given the example of if you spent £ten0,000 on a piece of research and it actually is proven, in behind you will come the bigger charities that would put in the million that takes it to the next phase, and in behind them will come the bio-checks that'll provide biotechs that'll provide the tens of millions.    And then, you know, a lot of what happens relies on serendipity as well, we know that, and you could easily run away with the idea that you made everything happen but you don't, you stand on the shoulders of others. And our very first grant application in our first grant round, which received extraordinary peer review for how excellent the application was, was a £100,000 project for a 3-year project that had gene therapy at the core of it by a researcher called Dr Ana Buj Bello at Généthon in Paris. This piece of research was so promising that 18 months in she and another researcher were able to raise $780,000 and, as Professor Muntoni predicted, from the French muscle disease charity AFM and the American muscle diseases charity MDA.  And 18 months into that 3 years it was so promising that a biotech company was started up with $30 million funding, literally just on her work.    So that doesn't always happen but, as Professor Muntoni explained, our job was not that $30 million, our job was that first £100,000, and our job was also to make ourselves known to the people in the neuromuscular field.  If you have lab time, if you have research time and you have a choice where you're putting it there is a place you can go to for a myotubular myopathy related grant application, so it's not just that this will come to us out of the blue, people will have done prior work, and our existence makes it worth their while, hopefully, to have done that prior work.  Ana Lisa: That's an amazing story how you've set up this charity and how successful that first application for gene therapy was. I'd love to hear more about that gene therapy and did it get to the clinic and to hear that story from you.  Because I think there are a lot of learnings and it's really important that the first patients who are treated, the first families that are involved, the researchers who start researching in this area, the first treatments lead the way and we learn for all the other treatments for all the other rare conditions that we hope and that together as a community we can share these learnings.  Anne: Yeah. I sometimes describe it a bit like going out into space. When you see a rocket going off look at how many people are behind and the amount of work that's been done, the degree of detail that's managed, and then you go out into space and there are a whole load of unknowns, and you can't account for all of them.  Who knows what's out there in this sphere.  But the amount of preparation, it feels similar to me now, looking back.  We were so idealistic at the beginning.  Our grant to Dr Buj Bello was 2008 and actually it is a really fast time in, the first child was dosed in the gene therapy trial in September 2017.  Ana Lisa: So, we're talking less than 1 years.  Anne: Yeah. And in the meantime obviously as a charity we're also funding other proof of principle research. One of the founding principles of the charity was to have a really excellent peer review process and scientific advisory board so that we wouldn't get carried away with excitement about one lab, one research team, that everything would always come back to peer review and would be looked at coldly, objectively. I don't know how many times I've sat in a scientific advisory board meeting with my fingers crossed hoping that a certain application would get through because it looked wonderful to me, and then the peer review comes back and there are things you just don't know as a patient organisation. So, yes, in those 9 years we were also funding other work.  Ana Lisa: You've just given an interesting perspective on sharing the learnings between the scientists, clinicians, the experts in a particular condition, if you like, and the families, and I'd be really interested to hear your views on what's been learnt about how families and the patient community can also teach the clinical and scientific community.  Anne: So, the first child was dosed in September 2017 and by the World Muscle Society Conference 2 years later in October 2019 the biotech had some fantastic results to show. Children who had been 24-hour ventilated were now ventilator-free, which, unless you know what it's like to have somebody in front of you who's ventilator-dependent, the idea that they could become ventilator-free is just extraordinary.    However, one of the things we've learnt about gene therapy is that we are going out into space so there are extraordinary things to be found, and extraordinary results are possible, as is evidenced here, but there is so much that we don't know once we are dealing with gene therapy. So unfortunately, in May, June and August of 2020, 3 little boys died on the clinical trial. So we have a clinical trial where the most extraordinary results are possible, and the worst results are possible, and both of those things are down to the gene…  What we discovered and what is still being uncovered and discovered is that myotubular myopathy is not just a neuromuscular disorder, it is a disorder of the liver too, and these children didn't die of an immune response, which is what everybody assumes is going to happen in these trials, they died of liver complications.    And one of the things that has come out of that, well, 2 sides to that. Number one is that it is extraordinary that we have found a treatment that makes every single muscle cell in the body pick up the protein that was missing and produce that protein, but also what we've understood is that the knowledge and experience of families and patients is even more vital than we've all been going on about for a long time. Because the issue of there being a liver complication in myotubular myopathy has been hiding in plain sight all this time, because if you asked any family they would tell you, “Yes, my son has had the odd liver result, yes.”    We could see something that looked like it was not that relevant because it was outside the big picture of the disease, which was about breathing and walking and muscles, but actually there was this thing going on at the same time where the children had liver complications. There were some very serious liver complications but everybody thought that was a minor issue but if we are able to engage the people who live with the disease and the people who observe the disease at a much more fundamental level we may be able to see more about what these rare genes are doing.  Ana Lisa: Yeah, thank you very much for sharing such a moving story and with such powerful lessons for the whole community about how we listen to the expertise that families have about their condition, and also I think the really important point about how we tackle the research funding so that we're including and sharing learnings from the conditions that are initially studied in greater depth, and we hope that many more conditions will be better understood and more treatments found and that actually the learnings from these first gene therapy trials will really help inform future trials, not just for gene therapies but also for many other novel therapies that are being developed.  [Music plays] If you're enjoying what you've heard today, and you'd like to hear some more great tales from the genomics coalface, why don't you join us on The Road to Genome podcast. Where our host Helen Bethel, chats to the professionals, experts and patients involved in genomics today. In our new series, Helen talks to a fantastic array of guests, including the rapping consultant, clinical geneticist, Professor Julian Barwell, about Fragile X syndrome, cancer genomics and a holistic approach to his practice - a genuine mic-drop of an interview. The Road to Genome is available wherever you get your podcasts. [Music plays] Ana Lisa: Carlo, I would really like to come to you about some of the initiatives that are happening in the UK, and particularly it would be really interesting to hear about the UK Platform for Nucleic Acid Therapies as a sort of shining example of trying to do something at a national scale across potentially many different rare conditions.    Carlo: Thanks, Ana-Lisa. Thanks very much, Anne, for sharing your fantastic story. I mean, I just want to iterate that as clinician scientists we do constantly learn from experiences and constantly learn from you, from the patient community, and this is absolutely valuable to push the boundary. And I really liked your vision of a rocket being launched in space and I would imagine that this is a similar situation here. So, we are facing a major challenge. So, there is over 7,000 rare diseases in the world and with improvements of genetic diagnosis this is only increasing. So, in a way rare diseases is the ultimate frontier of personalised medicine and this poses incredible challenges.   So, you mentioned the bottom-up approach and the top-down approach and in a way, both are absolutely necessary. So your story is a fantastic story but also makes me think of all the other families where they don't share perhaps the same spirit, you know, they are in areas of the world that are not as well connected or informed, where patient community simply cannot be ‘nucleated', let's say, around the family. So, there is definitely an issue of inclusivity and fair access.    So, what we're trying to do at UPNAT, which is the UK Platform for Nucleic Acid Therapy, is to try to streamline the development both at preclinical and clinical level of nucleic acid therapies. So, we'll start with antisense oligonucleotides just because those are the molecules of the class of drugs that are most ‘mature', let's say, in clinic. So, there are several antisense oligonucleotides already approved in the clinic, we know that they are reasonably safe, we understand them quite well, but of course the aspiration is to then progress into other forms of gene therapy, including gene editing approaches, for example.   And one of the activities that I'm involved, together with Professor Muntoni, is to try to streamline the regulatory process of such therapies and in particular curate a registry of, for example, side effects associated with nucleic acid therapy in the real world, and you would be surprised that this is something that is not yet available.  And the point is exactly that, it's trying to understand and learn from previous mistakes perhaps or previous experiences more in general.    And this is very much in synergy with other activities in the UK in the rare disease domain.  I'm thinking of the Rare Disease Therapy Launchpad, I'm thinking of the Oxford Harrington Centre, I am thinking of the recently funded MRC CoRE in Therapeutic Genomics. These are all very synergistic. Our point is we want to try to amplify the voice of the patient, the voice of the clinicians working on rare disease, and we want to systematise. Because of course one of the risks of rare disease therapies is the fragmentation that we do all these things in isolation. And I would argue that the UK at the moment leveraging on the relatively flexible and independent regulatory agencies, such as the MHRA, on the enormous amount of genetics data available through Genomics England, and of course the centralised healthcare system, such as the NHS, is really probably the best place in the world to do research in the rare disease area, and probably I'm allowed to say it because I'm a non-UK native.       Ana Lisa: Thank you, that's a brilliant perspective, Carlo, and across all the different therapeutic initiatives that you're involved with. And, Carlo, presumably - we're all hoping - these different initiatives will actually lead to ultimately a bigger scaling as more and more novel therapies that target both our RNA and DNA and actually are working, I guess further upstream in the pathway.    So classically in the past it's been necessary to work out all the underlying biology, find a druggable target somewhere in that pathway and then get a larger enough clinical trial, which can be nearly impossible with many of the rare and ultra-rare conditions or even, as you've said, the sub-setting down of more common condition into rarer subtypes that perhaps can be treated in different ways.  And with the many new different treatments on the horizon, ASO therapies, as you've said, is a place that's rapidly expanding, and also crisper gene editing. I'd be really interested to hear your reflections on how this might scale and also how it might extend to other new treatments.  Carlo: Yeah, that's exactly the right word, ‘scaling up'. I mean, there will be of course very unique challenges to every single rare disease but I would argue that with genetic therapies, such as ASOs or crisper gene editing, the amount of functional work that you need to do in a lab to prove yourself and the scientific community that this is the right approach to go for can be certainly very important but can be less just because you're addressing very directly because of the disease.    And then there are commonalities to all these approaches and possibly, you know, a platform approach type of regulatory approval might serve in that regard. You know, if you are using the same chemistry of these antisense oligonucleotides and, you know, similar doses, in a way the amount of work that you need to produce to again make sure that the approach is indeed a safe approach and an effective approach might be also reduced.    I would say that there are also challenges on other aspects of course, as you were saying, Ana-Lisa. Certainly the typical or standard randomised placebo control trial that is the standard and ultimate trial that we use in a clinical setting to prove that a molecule is better than a placebo is many times in the context of rare diseases simply not possible, so we need to think of other ways to prove that a drug is safe and is effective.   This is something that we all collectively as a scientific community are trying to address, and the alliance with the regulatory agencies, such as the MHRA, and you said that you have found your interaction with the MHRA very positive, and I can tell you exactly the same. So we are all trying to go for the same goal, effectively, so trying to find a way to systematise, platformise these sort of approaches. And I guess starting with antisense oligonucleotides is really the right place to go because it's a class of drugs that we have known for a long time, and we know it can work.  Ana Lisa: Meriel, can you tell us a little about the National Genomic Research Library at Genomics England and how this could link with initiatives to find many more patients as new treatments become available for rare and ultra-rare conditions?  Meriel: Yes, I think what's wonderful now is actually that what we're really trying to do is give everybody the opportunity to have their rare condition specifically diagnosed at the molecular level, and the way in which that is being done is by offering whole genome sequencing in the NHS currently in England but to all patients with rare diseases.    And so, it's about trying to establish their diagnosis. And as well as that, even if the diagnosis isn't definitely made at the first pass when the clinical scientists look at the data, because the whole genome has been sequenced, actually all that information about their genome, if they consent, can then be put into the National Genomics Research Library.  And that is a fantastic resource for national and international researchers who get approved to work in this trusted research environment to make new disease gene discoveries and identify these diagnoses for patients.  What's also offered by Genomics England as well is when the National Genomics Library data results in a new publication, the discovery of a new gene or perhaps a new molecular mechanism that causes a disease we already know about, that feeds back into the diagnostic discovery pathway within Genomics England back onto the diagnostic side of all the data.    So, patients who may have had genetic testing previously using whole genome sequencing where they've, if you like, had their sequencing done before the diagnosis was sort of known about, will also be picked up. And so, what this is really doing is trying to kind of give this really equal platform for everybody having testing to all have the same opportunity to have their diagnosis made, either on the diagnostic side or with research.  Ana Lisa: So, sort of on a cohort-wide scale as new discoveries are made and published you can go back and find those patients that may actually have that diagnosis and get it back to them, which is brilliant.  Meriel: Exactly. And this speeds up the whole process of getting these diagnoses back to people. So on a regular basis in the NHS, we will get feedback from the Diagnostic Discovery Pathway about “Here's some patients who you requested whole genome sequencing from a number of years ago and actually now we think we know what the particular molecular condition is.”  And so, it's key of course for our patients with rare conditions to make that molecular diagnosis because then we're able to have them identified for our colleagues who are doing this ground-breaking research trying to bring therapies for these rare conditions.  Ana Lisa: Thank you. And I hope that, as currently, if a novel genetic mechanism, as you've just described, is identified that could explain a rare condition that those patients can be found and they can receive that diagnosis, even many years later, and hopefully as novel treatments become available and say there's a chance to individualise ASO therapies, for example, to start with, that one could also go and look for patients with particular variants that could be amenable potentially to that treatment. And that's really sort of exciting that one could look for those patients across England, irrespective of which clinic they're under, which specialist they're under, and I think that could be really powerful as new treatments develop. I suppose, Meriel, if somebody comes to see you now in clinic are things different?  Meriel: Well, I think one of the things for me when patients come to clinic now is we might have an idea about what we think their condition is, maybe even we think it's a specific gene. And we can offer whole genome sequencing and so it's not just the way we used to do things before by looking just at the coding regions of the gene, we can find more unusual ways in which the gene can be perturbed using whole genome sequencing.  But let's say we don't make the diagnosis. I encourage my patients, if they're comfortable with it, to join the National Genomics Research Library, because really it's been incredibly productive seeing the new genetic discoveries that are coming out of that, but as well I say to them, even if we don't get the diagnosis the first time round when we look at the data, actually this is a constant cycle of relooking at their data, either if they're in the NGRL or as well on the Diagnostic Discovery Pathway side of the service that's run by Genomics England. So yeah, I feel like it's a very big difference; they don't have to keep coming every year and saying, “Is there a new test?” because actually they've had an excellent test, it's just developing our skills to really analyse it well.  Ana Lisa: Yes, and our knowledge, the technology and the skills keep evolving, certainly.  And I think one of the things that I'm sort of hearing from this conversation is that balance of hope and realism, Carlo we were talking about earlier how you need all the pieces of the puzzle to be lined up - so the regulatory agency, the clinicians, all the preclinical work has to have been done, monitoring afterwards for side effects - every piece of the puzzle has to be lined up for a new treatment to make it to a patient.    And, Anne, I'd like to come back to you because we've talked about this before, how one balances these messages of optimism and hope which are needed for bringing everybody together as a community to crack some of these very difficult challenges highlighted by treatments for rare and ultra-rare conditions and at the same time the need for realism, a balance conversation.  Anne: Yeah, that was one of our big learnings through the gene therapy trial and other trials we've had in the condition. As a rare disease charity, you do everything. You know, my title is CEO, but I tell people that's Chief Everything Officer because there's only a few of you and you do everything. So, you go and you lead the London Hope Walk and you also are a layperson on the Scientific Advisory Board and you also send out the emails about grants... And so, you could easily as a small rare disease charity conflate different communication messages because you're in a certain mode.  And so we have been from the early days in the mode of raising hope for people to say, “Look, we can make a difference as a patient community, we could raise funds, we might be able to move things forward, you've got the power to make a difference if you want to.” That's one set of hope.  And it's not dreamlike hope, we're linked to the reality of there are great breakthroughs.  So, you know, in the world of spinal muscular atrophy these clinical trials have led somewhere very quickly, so we're not selling false hope, we're talking about the difference we can make.    But then as soon as you flip into “There's a clinical trial being run” that's a completely different type of communication and you cannot conflate that message with the previous message.  And we always say to everybody, “We're your team, we're a family, we're a team, we all help each other.  When you are considering joining a clinical trial your team is the clinical trial team.    The other team does other things for you but the people you need to work with and ask hard questions of and listen hard to, that's your clinical trial team led by the principal investigator because then you're in that with them. And, you know, the reality of the fact that many, many clinical trials don't work as we wish they would be and the decision you make for your child, your baby, your little one, to join a clinical trial… because that's what it comes down to in our disease, has to be made with that team, not the team that's selling you a fundraising event. It's worth reminding rare disease patient organisations we're wearing different hats and the hope and the realism are different tracks you have to go down.    But at the same time as being realistic you also have to keep remembering that there is still grounds for hope, we are moving forward. And 21 years ago, when Tom was born the idea that you would be able to get all of the muscles in the body to switch back on – putting it in lay terms – seemed like a bit dream. Well, that is what has happened in the gene therapy clinical trial, we just have to now make it safer and understand more about what we're dealing with. So, the 2 things, the hope and the realism, do exist side by side.  Ana Lisa: I think that perfectly encapsulates a lot of the messages around rare disease therapies where there's such hope that novel treatments will really target directly the DNA or RNA to potentially correct the problem across many different rare conditions and therefore actually making treatments one day suddenly available to a much, much bigger population of people with rare conditions than we could've dreamt of 20 years ago or perhaps now, and at the same time this massive need to work cooperatively to all make this as fair, as equitable. Not everybody is going to have the opportunity to fundraise massively to be an expert about their condition, and the importance of sharing these learnings and also really, really listening to the patient community and really, as Carlo was saying, keeping track of side effects, having registries/databases to share these is going to be incredibly important.  [Music plays]  Ana Lisa:  Anne, can you tell us a little about your reflections on equity from the patient community perspective?  Anne: Well I mentioned serendipity early and one of the aspects of serendipity that played into our favour for setting up the Myotubular Trust was that by hook or by crook Wendy Hughes, who set up the charity with me, and I were both able to devote time at that period of our lives to setting up a charity. When my husband, Andrew, and I were told that Tom would more than likely die before his first birthday, one of the decisions we made as a family was that he would never not be with a parent, we would always have someone around, and that kind of meant someone had to give up a full-time job and that was me.  We thought, “If Tom has a few scarce months on the planet, we'll be with him.” And then when Tom lived to be nearly 4, as a family we got used to living on one salary and we were very lucky that we could pay the mortgage that way and run our family that way and eventually that meant I had the time to run the charity.    That doesn't happen that easily, that's a tall order, particularly when you have somebody in the family who has such high needs. And one of the things that I have often thought about is that in the rare disease space we could do with a different funding model for rare disease charities, we could, in an ideal world I have this nirvana that I imagine where there's a fund that you can apply to that is contributed to by the people who make profits out of finding rare disease cures - so the pharmaceutical companies and the biotechs - and there's a fund that they contribute to and that if you have a rare disease and you are willing to set up an organisation that supports families, that raises research funds, that provides a way of hearing the patient voice, then you could apply to that for running cost funds and then you'd be able to run this charity. And then you wouldn't have to rely on whether you live in an area where people will raise money for you or…  We were very lucky that we came across a few great benefactors who would give us money for running the charity, which is actually how we fund it.    All the research money we raise goes 100% into research, not a penny of it goes towards running costs because we have serendipitously found people who will be benefactors for the charity, but we're relying on a lot of good luck for that kind of model to work. And when you look at how much profit is made from developing rare disease treatments and cures – which is fine because that's what puts the passion and that gets people working on it – then why not have an advance fund to run rare disease charities? One of my nirvana dreams.  Ana Lisa: It's good to dream. Indeed, my hope is that there will be some amazing shining examples that lead the way that open doors, make things possible, prove that something can work and how and that then that will enable many other treatments for many additional rare conditions to be added in so that if you've learnt how this particular treatment modality works for this rare condition and there was funding behind it and everything else that's needed that then you can, the learning from that, I'm going to use the word ‘tweak', which sounds minor and could be very major but actually the concept that you can then tweak all those learnings and findings so that that same type of treatment modality could be adapted to treat somebody else with a different rare condition in a different location would be absolutely incredible and really powerful, given that if something like 85% of rare conditions affect less than one in a million people it's not going to be feasible to use the same strategies that have been used in the past for very common conditions.    One of the other big barriers is the cost of developing treatment for ultra-rare conditions.  Where it's a small number of patients that you have and therefore all the challenges that come with monitoring, checking for efficacy, monitoring safety and ultimately funding the challenges are much greater, however if some of these treatment modalities are also going to be used to treat common conditions it might be that actually there's a lot more cross-talk between the nano-rare, ultra-rare, rare and common conditions and that we can share a lot of that learning. I'd love to hear from each of you where you hope we will be for rare disease and rare therapies.  Carlo: Well my dream is that in 5 to 10 years' time an individual with a rare disease is identified in the clinic, perhaps even before symptoms have manifested, and at that exact time the day of the diagnosis becomes also a day of hope in a way where immediately the researcher, the centre, genetics lab, flags that there are the specific mutations, we know exactly which is the best genetic therapy to go after, antisense oligonucleotides as opposed to CRISPR editing, and a path forward, both at the preclinical and clinical level, to demonstrate and to cure these patients eventually is already laid out in front of the patient.  So, transforming the day of their diagnosis as a day of hope, this is my dream with the next ten years.  Ana Lisa: Thank you, that's a wonderful dream. Meriel, can I come to you?  Meriel: Yes, I think I just want to echo Carlo.  We've had great developments and progress with getting whole genome sequencing into the NHS for testing but what we really need is for it to be fast and efficient and getting those diagnoses established quickly. And we have had that set up now and we're really getting there in terms of speed, but then what we need is exactly what's the next step and actually structure like UPNAT that are developing these processes that we can then say to the patient, “And from there, now that we've established your diagnosis, this is what we have options to offer.”  Ana Lisa: Brilliant. And presumably that if the diagnosis isn't achieved now there is a hope that it will be achieved in the future as well. Anne...  Anne: Well, stepping one hundred per cent into the patient's shoes rather than the scientific side that we don't so much influence....  stepping in the patient's shoes, in 5 years' time I would absolutely love it if we were in a situation where all the parties that have come to the table looking at a therapy or in the earlier research genuinely want to bring the patient voice into the room. As Carlo talked about, there's even going to be more and more and more of these rare diseases, then those voices, those few people who have experience of it, they may be able to shed light on something. Maybe even sometimes don't even know it's a fact that they know but that were brought to the table as passionately as everything else is brought to the table.  [Music plays]  Ana Lisa: We'll wrap up there. Thank you so much to our guests, Anne Lennox, Carlo Rinaldi and Meriel McEntagart, for joining me today as we discuss the collaborative power of working together and look to the future of rare therapies that could have the potential to unlock treatments for many rare conditions. If you'd like to hear more like this, please subscribe to Behind the Genes on your favourite podcast app.  Thank you for listening.  I've been your host, Ana-Lisa Tavares. This podcast was edited by Bill Griffin at Ventoux Digital and produced by Naimah Callachand.  

Send us a textProf. Dr. Niels Riedemann, MD, Ph.D. is Chief Executive Officer and Founder of InflaRx ( https://www.inflarx.de/Home/About-Inflarx/Team~Niels-C.-Riedemann~.html ), a biopharmaceutical company focused on applying its proprietary anti-C5a and C5aR inhibitors to the treatment of life-threatening or debilitating inflammatory diseases with high unmet medical need. Prof. Dr. Riedemann has over 15 years of experience in the biotech industry and drug development, as well as over 20 years of experience in complement immunology research. He founded InflaRx in 2007 and has served as Chief Executive Officer since inception of the company. He has been instrumental in and led numerous private and public financing rounds of the company and has been the responsible lead for its Nasdaq IPO in 2017. He is named inventor on several internationally granted core patents of InflaRx. As physician, Prof. Dr. Riedemann was appointed Vice Director (“Leitender Oberarzt”) of Intensive Care Medicine, and led a 50-bed University ICU unit for over 6 years at Friedrich Schiller University, Jena, Germany until 2015. Before that, he received his board certification as General Surgeon upon completion of his surgical fellowship at MHH (Hannover Medical School, Germany) in 2007 where he also received his habilitation (equivalent to Ph.D.) and where he still holds an Adjunct Professorship (APL Professor). He spent three years as postdoctoral research fellow at the University of Michigan, USA until 2003. He received his medical training at Albert Ludwig University (ALU), Freiburg, Germany, and Stanford University, USA and graduated as Dr. med. (equivalent to M.D.) from ALU in 1998. Prof. Dr. Riedemann's research has been awarded with several national and international awards. He has received extensive extra-mural funding and published over 60 peer reviewed scientific publications in highly ranked journals. He has served as a member on a Board of Directors and a Scientific Advisory Board of two large scientific governmental funded programs. He currently serves as Co-Chair of the Health Politics working group of Bio-Deutschland and he serves as member of the board of trustees for the German Sepsis Foundation.#NielsRiedemann #InflaRx #Inflammation #ComplementComponent5a  #Sepsis #AcuteRespiratoryDistressSyndrome #Covid #ARDS #GOHIBIC #Vilobelimab #PyodermaGangrenosum #ChronicSpontaneousUrticaria #HidradenitisSuppurativa #Preparedness #BARDA #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Following the 2024 Marginal Zone Lymphoma (MZL) Workshop, CancerNetwork® spoke with multiple attending clinicians about insights they shared regarding the disease state, covering the significance of the workshop and its contribution to advancing research in areas such as prognostic factors and managing adverse events (AEs) related to the disease. Thomas Habermann, MD, professor of Medicine at the Mayo Clinic in Rochester, Minnesota, member of the Lymphoma Research Foundation's Scientific Advisory Board, and MZL Workshop co-chair, spoke about the significance of the MZL Workshop. He highlighted the complexity of these types of diseases, which he believed warranted the establishment of the group. According to Habermann, MZL is a “heterogenous group of disorders” that most contemporaries in the field “don't quite appreciate.” Next, Julie M. Vose, MD, MBA, George and Peggy Payne chair in oncology and chief of Hematology and Oncology at the University of Nebraska Medical Center, and co-editor-in-chief of ONCOLOGY®, spoke about how the MZL Workshop contributes to advancing research and improving outcomes for patients with MZL. She emphasized a need to be more inclusive when enrolling patients with MZL in clinical trials. Then, James R. Cerhan, MD, PhD, professor of Epidemiology at the Mayo Clinic College of Medicine and Science, and Ralph S. and Beverly Caulkins Professor of Cancer Research, spoke about addressing research questions in MZL epidemiology to further disease understanding. He emphasized a need to further study newly identified risk factors of the disease, as well as identifying new treatment targets for patients with MZL. Additionally, Alexandar Tzankov, MD, surgical pathologist and head of the Department of Histopathology and Autopsy at the Institute of Medical Genetics and Pathology at University Hospital Basel, and chair for the European Bone Marrow Working Group, discussed how prognostic factors for MZL may influence treatment. He described how the limited number of studies done with relatively small subsets of patients makes prognoses challenging, as prognostic factors have not been sufficiently explored. Finally, Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, outlined challenges related to AE management of treatments for MZL. He emphasized that safety management practices for MZL are comparable with other B-cell lymphomas, suggesting that use of bridging therapy for CAR T cells and step-up dosing for bispecific antibodies may help with mitigating AEs.

Send us a textBarbara Scolnick, MD is a graduate of Columbia University College of Physicians & Surgeons and board certified in internal medicine and addiction medicine. Barbara developed the ketogenic/ketamine treatment for anorexia as a pathway out of anorexia to help her niece, our former guest Caroline Beckwith, who we hosted on episode 759 of Boundless Body Radio, recover from the disease.Barbara is the author of two seminal articles on the ketogenic diet and ketamine for anorexia, including groundbreaking case studies reporting remission from chronic anorexia nervosa.She is the co-author of the book Exiting Anorexia: A Revolutionary Keto Metabolic Treatment for Anorexia from the Perspectives of the First Patient, the Physician/Researcher, and the Patient's Mother.She is also on the Medical and Scientific Advisory Board of Anor-Exit, an online program that calls for a ketogenic metabolic therapy to reverse eating disorders. The mantra that “all food is good food,” often fails to achieve a sustained recovery, while Ketogenic Metabolic Therapy has been shown to substantially weaken or eliminate the anorexic voice, anxiety, and behavior.Find Barbara Scolnick, MD at-Email- scolnickbarbara@gmail.comhttps://www.anorexit.com/Find Boundless Body at- myboundlessbody.com Book a session with us here!

Dr. Michael Biamonte is the founder of the Biamonte Center for Clinical Nutrition. He is a co-creator of BioCybernetics, which is an unprecedented computer software program that is able to study blood work, mineral tests and many other lab tests to determine exactly where your body is imbalanced initially designed for aerospace purposes.  As a practitioner for over 30 years, he is dedicated to improving the lives of his patients and helping them get back to living.  He holds a Doctorate of Nutripathy and is a New York State certified Clinical Nutritionist. He is a professional member of the International and American Association of Clinical Nutritionists, The American College of Nutrition and is a member of the Scientific Advisory Board for the Clinical Nutrition Certification Board. He is listed in “The Directory of Distinguished Americans'' for his research in Nutrition and Physiology.     In this episode you will discover:    Impact of Candida on the Immune System: Understand how candida overgrowth can weaken your immune system and make you more susceptible to infections.  Candida and Chronic Fatigue Syndrome: Learn about the connection between candida and chronic fatigue syndrome, and how addressing candida can improve energy levels.  Mental Health and Cognitive Function: Discover how candida overgrowth can affect mental health and cognitive function, leading to symptoms like brain fog and mood swings.  Dietary Recommendations for Candida: Get insights into the dietary changes that can help manage and treat candida overgrowth effectively.  Role of Parasites in Health: Explore the prevalence of parasites in Dr. Biamonte's practice and his approach to treating them, along with his thoughts on various diets like Keto, Carnivore, and Vegan.     Connect with (guest name)     Website: www.health-truth.com  Facebook:  https://www.facebook.com/The-Biamonte-Center-241435772676317/  YouTube: https://www.youtube.com/channel/UCiss7csT6pBnPAyeNA5AbDQ     Connect more with Dr. Kiltz    Website: https://www.doctorkiltz.com/     Keto + Carnivore Support - Group Kiltz Mighty Tribe: https://kiltz-mighty-tribe.mn.co/      Kiltz Cups: https://kiltzcups.com/     Doctor Kiltz Nutritional Solutions: https://www.doctorkiltznutritionalsolutions.com/     Instagram: https://www.instagram.com/doctorkiltz/      Tiktok: https://www.tiktok.com/@doctorkiltz    Facebook: https://www.facebook.com/doctorkiltz    Twitter: https://mobile.twitter.com/doctorkiltz    Amazon: https://www.amazon.com/Robert-Kiltz/e/B005EIXDWU%3Fref=dbs_a_mng_rwt_scns_share      Books by Dr. Kiltz: https://www.doctorkiltz.com/books-by-dr-kiltz/

Save 20% on all Nuzest Products WORLDWIDE with the code MIKKIPEDIA at www.nuzest.co.nz, www.nuzest.com.au or www.nuzest.comCurranz Supplement: Use code MIKKIPEDIA to get 20% off your first order - go to www.curranz.co.nz  or www.curranz.co.uk to order yours Today on the podcast, Mikki speaks to Kristi Storoschuk, a passionate researcher, science communicator, and PhD candidate at Queen's University. Kristi's research focuses on exercise physiology, metabolic health, and the fascinating world of nutrient-exercise timing.In this episode, we dive into topics like mitochondrial biogenesis, behind fasted versus fed training, and Kristi's broader research interests in improving metabolic health and blood sugar regulation. Kristi also shares her insights on the practical applications of her work, touching on how science can inform our day-to-day choices in nutrition and exercise.Whether you're an athlete, a coach, or simply interested in optimising your health, this conversation is packed with actionable advice and thought-provoking science. Kristi Storoschuk is a researcher, science communicator, and PhD candidate in the Muscle Physiology Lab at Queen's University in Kingston, Ontario. Her academic work focuses on exercise physiology, metabolic health, and nutrient-exercise timing, with a particular interest in how these factors influence mitochondrial biogenesis and blood sugar regulation.Kristi's passion for health and nutrition stems from her early experiences working in her family's health food store. This foundation inspired her journey into research, where she bridges cutting-edge science with practical strategies to improve metabolic health and promote healthy aging.In addition to her academic pursuits, Kristi has over three years of experience writing on topics such as ketogenic diets, fasting, and metabolic therapies. She has contributed to platforms like Paleo Magazine, CrossFit, and the Zero Longevity app, and serves on the Scientific Advisory Board at Keto Kind. She is also a sought-after speaker and science communicator, known for her ability to make complex topics accessible and engaging. Contact Mikki:https://mikkiwilliden.com/https://www.facebook.com/mikkiwillidennutritionhttps://www.instagram.com/mikkiwilliden/https://linktr.ee/mikkiwilliden

In this episode, our guests discuss the potential of large-scale health datasets to transform research and improve patient outcomes and healthcare systems. Our guests also delve into the ethical, logistical, and technical challenges that come with these programmes. We hear how organisations such as UK Biobank, Our Future Health, and All of Us are collecting rich, diverse datasets, collaborating and actively working to ensure that these resources are accessible to researchers worldwide. Hosting this episode is Dr Natalie Banner, Director of Ethics at Genomics England. She is joined by Dr Raghib Ali, Chief Medical Officer and Chief Investigator at Our Future Health, Professor Naomi Allen, Professor of Epidemiology at the Nuffield Department of Population Health, University of Oxford, and Chief Scientist for UK Biobank, and Dr Andrea Ramírez, Chief Data Officer at the All of Us Research Program in the United States. "There are areas where academia and the NHS are very strong, and areas where industry is very strong, and by working together as we saw very good examples during the pandemic with the vaccine and diagnostic tests etc, that collaboration between the NHS and academia industry leads to much more rapid and wider benefits for our patients and hopefully in the future for the population as a whole in terms of early detection and prevention of disease." You can download the transcript or read it below.  Natalie: Welcome to Behind the Genes   Naomi: So, we talked to each other quite regularly. We have tried to learn from each other about the efficiencies of what to do and what not to do in how to run these large-scale studies efficiently. When you are trying to recruit and engage hundreds of thousands of participants, you need to do things very cost effectively. How to send out web-based questionnaires to individuals, how to collect biological samples, how the make the data easily accessible to researchers so they know exactly what data they are using.   All of that we are learning from each other. You know, it is a work in progress all the time. In particular you know, how can we standardise our data so that researchers who are using all of us can then try and replicate their findings in a different population in the UK by using UK Biobank or Our Future Health.    Natalie: My name is Natalie Banner, and I am Director of Ethics at Genomics England. On today's episode we will be discussing how we can unlock the potential of large health datasets. By that I mean bringing together data on a massive scale, including for example genomic, clinical, biometric, imaging, and other health information from hundreds and thousands of participants, and making it available in a secure way for a wide range of research purposes over a long time period.   Through collaboration and industry partnerships, these programmes have the potential to transform research and deliver real world benefits for patients and health systems. But they also come with challenges ranging from issues in equity and ethics through to logistics, funding, and considerable technical complexities. If you enjoy today's episode, we would love your support. Please like, share, and rate us on wherever you listen to your podcasts.     I'm delighted to be joined today by 3 fantastic experts to explore this topic. Dr Raghib Ali, Chief Medical Officer and Chief Investigator at Our Future Health. Professor Naomi Allen, Professor of Epidemiology at the Nuffield Department of Population Health, University of Oxford, and Chief Scientist for UK Biobank, and Dr Andrea Ramírez, Chief Data Officer at the All of Us Research Program in the United States.   Andrea, if I could start with you. It would be really great to hear about All of Us, an incredibly ambitious programme in the US, and maybe some of the successes it has achieved so far.   Andrea: Absolutely. Wonderful to be here with you and thank for you for the invitation. The All of Us Research Program started in 2016 from the Precision Medicine Initiative and was funded with the goal of recruiting 1 million or more participants into a health database. That includes information not only from things like biospecimens including their whole genome sequence, but also surveys that participants provide, and importantly linking electronic health record information and other public data that is available, to create a large database that researchers that access and use to study precision health.   We have recruited over 830,000 participants to date and are currently sharing available data on over 600,000. So, we're excited to be with your audience, and I hope we can learn more and contribute to educating people listening about precision medicine.   Natalie: Thank you, Andrea. And not that this is competitive at all, but Raghib, as we are recording this, I understand the Our Future Health programme is marking quite a phenomenal milestone of 1 million participants. Would you mind telling us a little bit about the programme and something that you see as the benefits of working at scale for health research.   Raghib: Thank you very much. So, Our Future Health is a relatively new project. It was launched in 2020 with the aim of understanding better ways to detect disease as early as possible, predict disease, and intervene early to prevent common chronic diseases. Similar to All of Us, we are creating a very large database of participants who contribute their questionnaire data, physical data, genetic data, and linkage to healthcare records, with the aim as I said, to really improve our understanding of how best to prevent common chronic diseases.   So, we launched recruitment in October 2022. Our aim is to recruit 5 million participants altogether, and in the last 2 years about 1.85 million people have now consented to join the project. But you are right, as of last week we have what we call 1 million full participants, so people that have donated a blood sample, completed the questionnaire, and consented to link to their healthcare records. In our trusted research environment, we now have data on over 1million people available for researchers to use.   Of course, we have learnt a lot from the approach of UK Biobank, which we are going to hear about shortly, but the resource is open to researchers across the world, from academia, from the NHS, from industry, so that will hopefully maximise the benefits of that data to researchers, but as I say with a particular focus on early detection, early intervention, and prevention research.   Natalie: Thank you Raghib. Great to have you with us. Naomi, Raghib mentioned that UK Biobank has been running for a long time, since 2006.  It is a real success story in terms of driving a huge range of valuable research efforts.  Could you talk to us a little bit about the study and its history and what you have learned so far about the sort of benefits and some of the challenges of being able to bring lots of different datatypes together for research purposes?   Naomi: Yeah, sure. So, UK Biobank started recruiting 0.5 million participants in 2006 to 2010 from all across the UK with a view to generating a very deep dataset. So, we have collected information on their lifestyle, a whole range of physical measures. We collected biological samples, so we have data on their genomics and other biomarkers. Crucially because they recruited 15+ years ago, we have been able to follow up their health over time to find out what happens to their health by linkage to electronic healthcare records. So, we already have 8,000 women with breast cancer in the resource, cardiovascular disease, diabetes, and so on.   But perhaps most importantly, not only does it have great data depth, and data breadth, and the longitudinal aspect, is the data is easily accessible to researchers both from academia and industry, and we already have 18,000 researchers actively using the data as we speak, and over 12,000 publications already generating scientific discoveries from the resource.      Natalie: So, we have got 3 quite different approaches. Recruiting in different ways, different scale, different depth of data collection and analysis, but all very much around this ethos of bringing lots of different datatypes together for research purposes. I wonder if you could talk a little bit about how you might be sort of working together, even though you have got slightly different approaches. Are there things that you are learning from one another, from these different data infrastructures, or how might you be looking in the future to work together to address some of the challenges that might come up from working at scale?      Naomi: So, we talk to each other quite regularly. We have tried to learn from each other about the efficiencies of what to do and what not to do in how to run these large-scale studies efficiently. When you are trying to recruit and engage hundreds of thousands of participants, you need to do things very cost effectively. How to send out web-based questionnaires to individuals, how to collect biological samples, how to make the data easily accessible to researchers so they know exactly what data they are using.   All of that we are learning from each other, and you know it is a work in progress all the time. In particular, how can we standardise our data so that researchers who say are using All of Us can then try and replicate their findings in a different population in the UK by using UK Biobank or Our Future Health. So, can we come up with common standards so that researchers can better directly compare the data that they are using? So, we are in close contact with each other.   Natalie: Fantastic, thank you. And Andrea, from your perspective obviously you are collecting data in the US. Are you finding ways of working internationally and with other infrastructures like Biobank and Our Future Health around things like data standards? It sounds like something simple, but I can imagine it is quite complex in practice.   Andrea: Absolutely, and that dialogue and understanding and learning from each other both informally in meetings and talking as well through the published literature. So, all of these datasets are actively widely used, and seeing what is coming out in publications helps us know what researchers are doing with the data. And when you see different researchers either generating hypotheses from our datasets in a different way, or testing hypotheses differently, that helps us understand where some benefit might be added to our dataset or where we really may need to grow in a different direction to meet some other research needs.   I think that every study design always struggles with that balance between knowing exactly what we want to study and therefore building very specific questions and very specific protocols, but also allowing for the knowledge that we don't really know all of the discovery we need to make and bringing in datapoints that will really generate those new hypotheses for the future.     I think for our study in particular, UK Biobank has been so remarkable in this way, helping structure All of Us to be able to contact our participants like UK Biobank and say, “Hey, we didn't really know what we were going to get, but we have put all this wonderful data together and now we need to do a deeper dive.”   So, the engagement and long-term return of those UK Biobank participants has really enriched our data, and we have learnt from UK Biobank a lot there, and hope through growing our partnerships programme that we can continue to create partnered research opportunities to strengthen that data as well. That is a new thing coming out of our group. You may have heard of it previously as ancillary studies, but we recognise the partnership that is important for those research opportunities. So, we are reporting here that we are hoping to rebrand it to reach a larger audience, and that is led by Dr. Shelley, as partnered research opportunities that will allow us to re-contact, bring our participants back, and really deepen that dataset.   Natalie: Thank you. And Raghib, I know that it is a really important part of the Our Future Health model about going back to participants, but you are in quite early stages of working out what those opportunities might look like.   Raghib: Yes, very much early stages. Just to reiterate the point for me personally, having started my research in the UK about 20 years ago, I have certainly learnt a lot personally, but we have all learnt a lot from the model that UK Biobank established in terms of collecting data and providing it to researchers, and I see these 3 studies as very much complimentary.   All of Us again have done a lot more work in terms of providing feedback to participants about their risk of disease and genetic information, and as you say Our Future Health was set up deliberately to not just be a purely observational study, but to give participants feedback about their risk of different chronic diseases as well as the opportunity to take part in not just studies to collect data, but also interventional studies to see if we can change the natural history of disease and prevent diseases in our participants.   So, that has never really been done at scale before, and that is certainly a big challenge for us to do, not just in the UK, but anywhere, including the US and working with health systems as to how best to do that. So, you know we have spent the last 2 years really trying to understand how best to recruit participants and to provide data to researchers for the next couple of years, and long beyond that we will be looking really as to how we can maximise the benefits of providing feedback to participants and taking part in interventional studies.   Naomi: I think one way in which we can all learn from each other actually, is we know how to recruit hundreds of thousands of people, the general population, into research study, and the next challenge is how do you keep engaging them, telling them what you are doing. You can't collect everything when they first join the study, or they would be with you for days. So, what UK Biobank has been doing is sending out web-based questionnaires, a couple a year, to find out extra information about health outcomes, lifestyle factors. Inviting them back to specific assessment centres.   So, we are inviting 100,000 participants back for imaging, and then again over the next few years for a second scan. So, I think the real challenge here is once you have recruited them, how to find that right cadence of engaging those participants to keep contributing their data and their biological samples to really maximise the value of the dataset for research. That is an ongoing challenge for all of us. But I have to say, the UK Biobank participants, they are an amazing group of individuals, very altruistic.   Our Future Health and All of Us, we don't give feedback, so there is nothing in it for our participants other than knowing that their data may help the future health of their children, and their grandchildren, and the rest of the world. So, that is very humbling, to know that the data that they have generated, and we have collected on them, is being used in that way.   Natalie: That's a really interesting point, Naomi, about the difference between a research study that is designed for answering a particular question. You gather specific data for a specific purpose, and when it comes to recruiting participants into that you can be very clear about what it is you are trying to do.   But of course, for all of these programmes, the whole nature of them is that you are collecting a lot of data over a long period of time, and it could be used for all sorts of different purposes. You can't say at the outset exactly what those purposes might be and what those outcomes might be. So, there is a really interesting question, and of course I would say this with my ethics hat on, a really interesting question around sort of participant trust and confidence in those programmes.   Naomi, you spoke just then about one way of retaining engagement and retaining people's interest, but I wonder Raghib and Andrea, if you have got thoughts on those sort of questions of how you can create that environment where participants can trust what you are doing with data over a long period of time, when you can't at the point at which they consent, say exactly how that data might be used? You have got a sense of the kinds of purposes, but you can't be too specific         Andrea: Sure. We know, and I have learnt from my own peers in this role, that enrolment in the study isn't the end point of engagement. All of Us's approach on engagement has been communicating with the entire community and really being there in the community, and that has been very powerful.   One effort over the last year we are proud of has been what we are dubbing participant driven enquiry, and that is where we say, “Thank you participants. We have gotten a ton of data out there for use, and funded researchers to use it all the time, but what do you, the participants, really want?” We were able to then take papers that researchers write and help tell participants and explain it in lay language, so the participants can say, “Hey, I have a question. Could you answer that for me?” Maybe we can, maybe we can't, but it has been very interesting to hear what participants want to know, and that participant driven enquiry project has turned out to be a big opportunity there.    The question they came to was not easy. Certainly, we didn't expect an easy question, but they came to us asking, “Why is my diabetes worse than someone else's? Is it the environment? Is it my genome? Is it my access to care? Why can't my diabetes be as well controlled as someone else's?”  So, that has been huge, to interact directly with our participants and help really close the loop by answering questions in the language of research and show them how their data is contributing back.    Natalie: Thank you. And Raghib, how are you sort of grappling with these questions, particularly because you are recruiting so very heavily at the moment?   Raghib: So, as you say it is a challenge, and people do join the programme primarily based on trust that we will use their data for public health benefit and for the benefit of the whole population, but they also join on the basis that they will get back information about their own health and their risk of disease. To do both of those is not straightforward. I mean, the first of those, it has been well established by UK Biobank, and about 80% of our participants also say they are doing it primarily for to altruistic reasons, which is great. But 80% also said they would like to receive feedback about their own health, which is also understandable, and so we need to find ways to provide that in a timely way, but also in a way that the health service can manage. That is going to be one of our key challenges going forward.    But to echo what Naomi and Andrea have said, I mean to maintain participant's engagement with the programme is not easy. We need to make sure that they are receiving information regularly, are kept up to date with what we are doing with their data, with the work that we are doing with academia, with the NHS, with industry etc. It is easier now than it was before because Our Future Health has been set up as a digital cohort, so we have means of communicating much more easily with our participants. But yeah, as you say we are at early stages. Over time that does get harder, to maintain that engagement. So, we know in the next one to 2 years we need to step up our work on feedback and recontact.   Natalie: Fantastic. I really love the idea of like the participant-led enquiry. That is something that I think our participant panel at Genomics England would really like to hear more about.   So, speaking about sort of ongoing engagement with participants, one of the challenges we know around recruiting into large-scale studies like this is that many research datasets don't have equal representation from all communities. That might have an impact on the quality, the representativeness of the scientific outputs that you can generate, and potentially the benefits back to patients and participants.   How are you addressing this challenge in recruitment where you may have some communities that are not as engaged with scientific research. You may have elements of distrust or people being marginalised, having difficulty accessing research and these sorts of opportunities. Do you have any examples of what has worked really well? Raghib, if I could come to you first.   Raghib: Sure. So, I mentioned I worked on UK Biobank about 20 years ago. One of the things I was looking at then was how we could maximise participation, particularly of people from ethnic minorities into the project. Because of the age group that was chosen by UK Biobank for very good reasons, age 40 to 69, the proportion of people from ethnic minorities was relatively small. So, although it was representative for that age group, I think it was about 6%, or 34,000 out of the 500,000, that were from non-white ethnic minorities.   So, when Our Future Health was set up, we knew that the population has changed anyway. You know, the UK has become a much more ethnically diverse society. But also, because it is a cohort from 18+ and I think minorities tend to be younger on average than the white population, we knew we had an opportunity to really have a big step change in the number of people that could take part in a study like this. So, our aim is actually to get 10% of the whole cohort from ethnic minorities, so 500,000 out of the 5 million from ethnic minorities. Actually, so far we are pretty much on track. So, of the 1.8 million that have consented, about 180,000 are from non-white ethnic minorities.   That is extremely important, particularly for genetic research where non-European populations are very much underrepresented in nearly all genetic databases. Secondly, from a UK context, although it applies of course in all countries, is that people from more deprived backgrounds are also less likely to take part in this type of research. So again, we have made a very deliberate attempt to try and ensure we have adequate numbers from the most deprived quintile. Again, about 10% of the cohort so far, nearly 200,000 are from that most deprived quintile who both are underrepresented in research, but also have the worst outcomes. So, this is really our first study that has been big enough in the UK to look at that group properly and understand some of the factors at an individual level that we haven't been able to in the past.   Finally, geographically, so the first time again because it is a digital cohort, we were able to recruit people from all over the UK. So, every single part of the UK is now represented in Our Future Health, particularly coastal communities and rural areas that haven't been able to take part in this type of study before, as well as Northern Ireland. You know, for the first time we have got that full geographical coverage.   Natalie: Fantastic. I suppose a lot of that recruitment approach has very much been about going to where people are, rather than expecting them to come to you. Is that right?     Raghib: That is right and thank you for reminding me. So yeah, we have had a different approach. So, we have opened up many, many more clinics than previous studies through a combination of mobile units, shopping centres, community pharmacy. Community pharmacy in particular has been very important. So, to date we have had about 400 different venues that we have been able to recruit. That is over 1 million people that have given blood samples, and that has really enabled people from every part of the country to take part. Secondly, we have kept clinics open in areas of greater deprivation and ethnic diversity much longer than in other areas, to maximise the opportunity for them to join. Thirdly, we do provide reimbursement for people with expenses to ensure they aren't excluded because of financial reasons, and again that has helped.    Natalie: So, really making those efforts is evidently paying off. Andrea, have you had similar experiences as All of Us? What has your approach been to try and ensure that you are getting a wider representation from different communities?    Andrea: It has really been a focus on the programme from the start to engage those who have not been included in research in the past and make sure the opportunity is there to participate. Our Engagement Division, led by Dr. Corrine Watson has really pioneered reaching those communities here in the US.   I think one other thing I will mention that we think about when we think about how to engage participants and reach people to return value back to those communities, is to make sure the people who are accessing the data also represent them, and we can build diversity within that researcher workforce. So, since our data was first released in 2020, we have recognised that the biomedical workforce also has a huge group of underrepresented individuals, and a lot of our researcher engagement and researcher outreach has focused on reaching those of diverse backgrounds and career paths.   To that end we have reached out and engaged historically black colleges as well as other minority serving institutions, really looking to make sure that their students and researchers can have the same access as more traditional research-based institutions in the US system.    That has been important because our system is built on cloud-based architecture and shared data that doesn't require a huge cluster on campus, and that helps remove a barrier that some of those institutions and researchers may have had. We also know they haven't been able to participate in the past, and we think that cloud architecture again can make the data much more feasible and be a huge support to diversifying the researcher workforce as we go forward. That circling back, helping them be the voices speaking to their community, helps build out that diverse participant community base as well.    Natalie: That's such an important point, because it is not just about the participants and the data you can collect, but also who is able to look at it? Who is actually able to undertake the research?    Naomi, can I bring you in here? I know that UK Biobank has been thinking a lot about researcher access to data and trying to ensure that the data that you hold, the really rich datasets you hold in UK Biobank, are more accessible to researchers from different backgrounds who may not have the same level of resources. Can you tell us a little bit about the work you have been doing on that?   Naomi: Yeah. So, just following on from what Andrea said, it is really important to get as diverse ideas as possible from across the global research community to really move public health forward.   So, what UK Biobank has done is we are putting mechanisms in place so that early career students, and career researchers, and researchers at all levels of their career from lower income countries, can access the data at a much lower fee. So, currently for most researchers it costs about £9,000 to access all of the data. So, that is 40 petabytes of genomic data, biomarkers, clinical outcomes, lifestyle factors and so on. So, early career researchers and those in lower income countries, it is about £500.   On top of that a group of big pharmaceutical companies have got together to create a global researcher access fund, which essentially covers this reduced fee so that all researchers no matter where they are from have exactly the same opportunity to access the data to advanced scientific discoveries. So, on top of that all our researchers now use our online secure research analysis platform. While there is no charge to access the platform, there are costs associated with compute needed to analyse and store the results.    So, AWS have donated research credits for early career researchers and those from lower income countries up to a total of about $500,000 per year, to use the research platform. So, researchers can apply to use these research credits to offset the costs of compute and storage. So, that means that we are trying to democratise access to researchers from all around the world.   I think actually our biggest challenge is not so much … we have largely dealt with you know subsidising the cost. It is actually making researchers from lower income countries aware that these resources exist, and that are applicable to them.   So, sometimes we hear from say researchers in Africa or South America, “Well, there is no point accessing UK Biobank because it is not relevant to our population.” You know, a third of our researchers are from China. So, even if UK Biobank hasn't got coverage of those racial ethnic populations, that doesn't mean that the associations that you find between risk factors and disease risk are not applicable to other different populations. And that is also why having different resources like UK Biobank, like Our Future Health, like All of Us, in different populations around the world, is so important in order to replicate those findings.    Natalie: Absolutely, and fantastic just to hear the attention that is being paid to trying to ensure that diversity of different types of researchers who will just bring different questions to the table, different perspectives on the data, different priorities, different types of questions.    So, speaking about that diversity of researchers, one really important part of his ecosystem that we haven't really touched on so far is around the role of industry. There are a lot of really important research questions being addressed by industry. Some that can only really come from, maybe it is pharmaceuticals, maybe it is tech.   From your perspectives, what kind of role can and should industry and commercial partners play in supporting the kinds of long-term research studies that you have set up, and ultimately trying to get to that point of sort of generating benefits back to patients and health systems. Naomi, can I start with you, for that sort of longer-term perspective for Biobank?   Naomi: So, industry are great partners for long-term studies like ours because they can bring additional funding, expertise, and technology. So, for UK Biobank, because it is so easily accessible to industry and academics alike on exactly the same terms, what it has meant is that industry, particularly big pharma and also now big tech, they can access the data, they see the value of the data for their own research purposes, and then they have invested into UK Biobank to do whole-exome sequencing, whole genome sequencing, proteomics at scale to increase the value of the dataset for their own drug discovery pipelines.   But of course, it means that the data that they have generated, which cost millions of dollars to generate, when you need deep pockets to do these kinds of study enhancements, then become available to all researchers. So, having access to these large-scale resources that have deep data on genomics, physical measures, other biomarkers, and clinical outcomes enables pharma to rapidly increase their drug discovery pipelines in generating new drugs and treatments for patients, and also those data are then shared with the rest of the global research community.     So, we found it to be a really exciting win/win in which industry get what they need to help move forward new drug targets and discovery, but also other researchers get what they need in order to make other scientific discoveries in different fields of research.        Natalie: Thank you. And Raghib, I know that for Our Future Health, that industry relationship is a really important part of the founding model. Will you tell us a little bit about how you are engaging and working with industry partners?   Raghib: Sure. So, as you said Our Future Health was set up in a different way, as a very public private partnership. Although the largest funder is the UK Government, more than half of our funding has come from a combination of life science companies, so pharmaceutical, diagnostic companies, as well as the medical charities, so the larger medical charities in the UK. That partnership is deliberate for all the reasons that Naomi has outlined. There are areas where academia and the NHS are very strong, and areas where industry is very strong, and by working together as we saw very good examples during the pandemic with the vaccine and diagnostic tests etc, that collaboration between the NHS and academia industry leads to much more rapid and wider benefits for our patients and hopefully in the future for the population as a whole in terms of early detection and prevention of disease. So, we have 16 life sciences companies that have joined as founding partners with Our Future Health who have contributed financially to the programme.    Equally importantly they have also contributed scientifically, so there is a huge amount of scientific expertise in industry, and they work with us with our Scientific Advisory Board with our scientists internally to think about the best use of the resource for drug discovery, diagnostics, new medical technologies, and new targets etc.    So, that is the vision, and so far, it is working well. It is a relatively new model to have set up a project like this in this way, but it has been a very collaborative approach, and we all recognise, all have similar aims, so recognise what we are working towards. You know, we meet regularly. We have a Joint Founders Board where as I say academia, NHS, industry, and the charities come together to decide on the priorities for the coming years.   Natalie: Fantastic. And Andrea, I suppose in the US it might be slightly different culturally from the UK, but the role of industry with All of Us, how are you engaging with those pharmaceutical, technology bodies, and partners as well?     Andrea: Absolutely, and maybe this goes back a bit to your first question. We at All of Us love learning from UK Biobank and have really seen them forge a lot of wonderful partnerships that have enriched and developed their dataset. We at All of Us have started with academia and working through partnership opportunities really intramurally at intramural centres that make up parts of the National Institute of Health. We believe that building on those close friends and family relationships we have both in the government and academia get us through our first step to be able to interface with commercial organisations. That really started with taking the first step this year to ensure broad availability of data that can maximise both use of the data available, as well as look forward to our partnership opportunities in the future.   So, commercial organisations as of 2024 have also been able to access the All of Us dataset that is that first step in thinking about what a partnership would be, and we are glad to build on the access that international organisations and academic organisations already have.   Natalie: A lot to look forward to here. We are going to have to wrap up in a moment, so I'd just like to leave you all with a final question before we have to end the podcast. There is huge ambition in all of the research programmes that you are leading and involved in, but what are you most excited about coming down the line in the next few years? What do you think is going to be feasible? What really gets you excited about the work that you are doing and where you see the potential benefits really landing in the next few years? Andrea, would you like to start?   Andrea: Thanks. There is a lot we are really excited about. I haven't had a chance yet to mention our paediatric cohort, and that in addition to expanding access for international research, in 2024 we were able to enrol our first paediatric participants. That really sets up the potential to observe participants across the lifespan. That is a huge advance for All of Us and we are excited about the paediatric work going forward.    Natalie: I love that, how do you come into the future with us? That is fantastic. Naomi.   Naomi: Yeah, if I had to choose one would be the possibility of being able to measure circulating proteins on all half a million participants. We have done this on about 55,000 participants, and just that subset alone is already generating fascinating insights for early biomarkers for disease through protein profiles and risk prediction of disease. I think having that on all half a million coupled with their genomics data and health outcomes, will bring a sea change in how we diagnose disease earlier. So, I think that is a really exciting avenue for us to go into over the next couple of years.   Natalie: Really enriching. That data sounds like a very exciting set of possibilities. Raghib.   Raghib: Thank you. There are so many opportunities here, but I will just maybe mention 3. So, the first, in terms of being able to combine the genetic data that we are collecting and all the other information about risk factors, and particularly the fact that we have this on a lot of young people, will enable us to identify people at high risk of diseases in the presymptomatic phase and then to be able to offer them both feedback about their risk of disease but also interventions that can change their natural incidences. That has never really been possible before. That is extremely important for all diseases for people, but also it is very important for our healthcare system.   So, those of you listening in the UK, I know the NHS is under a huge amount of pressure, and the current model of healthcare which has been in place really since the inception of the NHS, is to treat late-stage disease when people have already developed symptoms and signs. You know, it wasn't really possible to identify people earlier, but it is now, and Our Future Health will provide the evidence base to show that prevention really is better than cure, and to show that these approaches both lead to better clinical outcomes, but also are cost effective and a good use of resources. Of course, the new government is very much committed to this as well, you know moving from acute care to prevention, from hospitals to community, and from analogue to digital.     Finally, because our cohort has now become so large and does cover every part of the UK, and this wasn't something I necessarily thought about when we started Our Future Health, we are able to have unique insights into the health of the population across every age group, across every ethnic group, across every geographical area, and by deprivation, and to understand not just observationally in terms of risk factors, but also the impact of interventions on those different populations.   We can look at that, as I said at an individual level on millions of people to gain intelligence about what is going on in terms of public health, but also to see what will hopefully improve their health in the future. So, there are really, you know I have described transformational opportunities to improve health through both biomedical research and populational health insights now through the resource, and I look forward to working with colleagues across the UK and globally to deliver them.   Natalie: We will wrap up there. Thank you so much to our guests, Dr Raghib Ali, Professor Naomi Allen, and Dr Andrea Ramírez for joining me today as we discussed how collaboration, scale, ongoing engagement, can really unlock the potential of large-scale health datasets to drive brilliant new research and ultimately improve the lives of patients and the population.   If you would like to hear more like this, please subscribe to Behind the Genes on your favourite podcast app. Thank you for listening. I have been your host, Natalie Banner. This podcast was edited by Bill Griffin at Ventoux Digital and produced by Naimah Callachand.

Send us a textIn this episode of Causes or Cures, Dr. Eeks sits down with Dr. Alan Lightman to explore "spiritual materialism," the idea that we can embrace awe-inspiring, spiritual moments without turning to the supernatural for explanations. Dr. Lightman shares insights from his new book, The Miraculous From the Material: Understanding the Wonders of Nature, and delves into profound topics like consciousness, near-death experiences, the possibility of a higher power, immortality, relationships, and whether falling in love leaves space for magic. If you love pondering life's biggest questions, this episode is a must-listen.Dr. Lightman is a renowned physicist, author, and entrepreneur. A former Harvard faculty member and current professor at MIT, he holds a degree from Princeton University and a PhD in physics from Caltech. He's the bestselling author of the modern classic Einstein's Dreams, The Diagnosis, The Transcendental Brain, and The Accidental Universe. Dr. Lightman also hosts the acclaimed PBS series Searching: Our Quest for Meaning in the Age of Science. Since 2023, he is a member of the United Nations' Scientific Advisory Board.This episode is sponsored by Greco Gum, the all-natural chewing gum for your mouth and gut. Visit GrecoGum.com and use code ERIN15 to get 15% off your first order!*New* SUBSCRIBE for Causes or Cures+ Bonus Episodes & Monthly Live Q&As!You can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Or Facebook here.Or X.On Youtube.Or TikTok.SUBSCRIBE to her monthly newsletter here. Support the show

Episode #244: This week on Balance Your Life podcast I am joined by Dr. Michael Biamonte. Dr. Biamonte is the founder of the Biamonte Center for Clinical Nutrition. He is a co-creator of BioCybernetics, which is an unprecedented computer software program that is able to study blood work, mineral tests and many other lab tests to determine exactly where your body is imbalanced, initially designed for aerospace purposes.  As a practitioner for over 30 years, he is dedicated to improving the lives of his patients and helping them get back to living.  He holds a Doctorate of Nutripathy and is a New York State certified Clinical Nutritionist. He is a professional member of the International and American Association of Clinical Nutritionists, The American College of Nutrition and is a member of the Scientific Advisory Board for the Clinical Nutrition Certification Board. He is listed in “The Directory of Distinguished Americans'' for his research in Nutrition and Physiology. On this episode we talk about nutrients in general that society is lacking as a whole, supplements we should be taking and ones to avoid. We also discuss what type of blood work, mineral tests, and lab work we should be having done, the truth about seed oils, what categories of testing we should be looking at, and so much more! Spread the love by sharing this podcast with your friends and family! Don't forget to subscribe to the channel so you never miss an episode, and I would love if you took a moment to rate and review the show! ------------------------------------- Connect with Meghan: Instagram | TikTok | YouTube | Website Connect with Dr. Biamonte: Website | Book To Email the Show: info@balancebymeghan.com -------------------------------- Download the Holiday Gift Guide and Wellness Wishlist 2024 here ------------------------- Shop my Amazon Store Front where I link all my favourite wellness, lifestyle, pregnancy, and beauty products and brands.  ------------------------------------------  Join me by practicing yoga and fitness in the comfort of your home! Click here for my YouTube channel.  ------------------------------------------                                Access the Yoga Mama Journey: Journey to a Happy and Healthy Pregnancy and Baby Program and Guide here.

Dr. Olivardia is a clinical psychologist, lecturer in the Department of Psychiatry at Harvard Medical School and Clinical Associate at McLean Hospital. He maintains a private practice in Lexington, MA, where he specializes in the treatment of ADHD, executive functioning issues, and issues that face students with learning differences. He is a recognized expert in the treatment of body dysmorphic disorder (BDD), eating disorders and obsessive-compulsive disorder (OCD). He is on the Professional Advisory Boards for Children and Adults with ADHD (CHADD) and The Attention Deficit Disorder Association (ADDA), as well as sits on the Scientific Advisory Board for ADDitude and the Expert Network for Understood. He is co-author of The Adonis Complex, a book which details the various manifestations of body image problems in males. He has appeared in publications such as Time, GQ, and Rolling Stone, and has been featured on Good Morning America, Extra, CBS This Morning, CNN, and VH1. He has spoken on numerous radio and webinar shows and presents at many talks and conferences around the country. He also has lived experience as someone with ADHD and learning differences and a parent of two teenagers with ADHD and Dyslexia. Key Takeaways: 1. ADHD and Eating Disorders: ADHD impacts all life domains, with symptoms like impulsivity, executive dysfunction, and high sensory needs that influence eating behaviors. For many with ADHD, eating is driven by sensory-seeking, and the brain's need for stimulation can lead to unhealthy eating patterns. ADHD is often associated with binge eating and food impulsivity, influenced by genetic and neurological factors, such as dopamine dysregulation and low levels of GABA, the neurotransmitter related to inhibition.   2. Genetics, Food Culture, and Neurobiology: Dr. Olivardia shares how his family's love for food shaped his relationship with eating and sensory stimulation. ADHD brains often experience high stimulation from ultra-processed foods, which can drive cravings and overeating due to dopamine's role in the brain's reward system.   3. Executive Function Challenges in Meal Planning: ADHD can make meal planning, shopping, and cooking overwhelming. Structured lists, simple recipes, and single-pot meals can help manage mealtime more effectively for those with ADHD. Regular, scheduled meals prevent intense late-night eating often seen in ADHD.   4. Medication and Treatment Options: Stimulant medications, like Vyvanse (FDA-approved for binge eating disorder), help some individuals with ADHD manage impulsivity around food by improving focus and reducing cravings. Proper medication can significantly enhance treatment outcomes for ADHD-related eating challenges. For individuals who don't respond to medication, behavioral strategies such as maintaining regular sleep schedules, exercising, and using music for grounding can be effective.   5. Binge Eating and Addiction Risks:  Dr. Olivardia highlights the link between ADHD and addiction, including food addiction. ADHD brains metabolize glucose differently, leading to cravings for high-sugar foods. Education on how ADHD brains work can alleviate feelings of weakness or shame in managing eating behaviors.   6. Self-Acceptance and Neurodiversity: Dr. Olivardia encourages embracing ADHD and neurodiversity, emphasizing that people with ADHD often excel in creative and mission-driven fields. ADHD challenges can become strengths, leading to fulfilling, meaningful work and connections.   Resources: • CHADD (Children and Adults with Attention-Deficit/Hyperactivity Disorder) – A leading organization for ADHD support and resources: https://chadd.org   • Attitude Magazine – A resource for ADHD insights and content: https://www.additudemag.com   The content of our show is educational only. It does not supplement or supersede your healthcare provider's professional relationship and direction. Always seek the advice of your physician or other qualified mental health providers with any questions you may have regarding a medical condition, substance use disorder, or mental health concern.    

November is National Men's Health Awareness Month in the United States. Registered Pharmacist Greg McKettrick is on the show today to talk about important men's health topics. Our conversation covers the Post Prostatectomy Penile Rehabilitation Protocol Greg developed, post-op urinary incontinence, erectile dysfunction, regaining sexual intimacy, mental health, medical devices, and more.    Patients, pharmacists, student pharmacists, urologists, and other healthcare professionals need to hear our conversation. If you know at least one person who could use the information in this episode, please share it with them.   Greg is a Men's Health Specialist and a compounding pharmacist. If men's health or compounding interests you as a pharmacist or a pharmacy student, reach out to Greg McKettrick, RPh. Connect on LinkedIn, Email Greg@revelationpharma.com, or call 704-883-2895.    Thank you for listening to episode 303 of The Pharmacist's Voice ® Podcast.   To read the FULL show notes (including all links), visit https://www.thepharmacistsvoice.com/podcast.  Select episode 303.   Subscribe for all future episodes.  This podcast is on all major podcast players and YouTube.  Links to popular podcast players are below. ⬇️   Apple Podcasts   https://apple.co/42yqXOG  Spotify  https://spoti.fi/3qAk3uY  Amazon/Audible  https://adbl.co/43tM45P YouTube https://bit.ly/43Rnrjt   Bio - Greg McKettrick (October 2024)   With over three decades of experience in the compounding industry, Greg McKettrick serves as a Clinical Liaison - Men's Health Specialist at Revelation Pharma, a national network of 503A and 503B compounding pharmacies dedicated to providing industry-leading pharmaceutical compounding services. Previously a compounding pharmacist at Stanley Specialty Pharmacy, Greg is a powerful voice in the world of men's health and men's sexual; wellness, drawing on his years of experience to elevate Revelation Pharma's industry presence.    In addition to his role at Revelation Pharma, Greg is a Chief Medical Advisor for the BHRT Training Academy, having designed the organization's Men's Health Module, and is on the Scientific Advisory Board for Berkeley Life Nitric Oxide. Greg is also a frequent speaker for Zerocancer groups and presentations.    A true thought leader in the industry, Greg developed his Post Prostatectomy Penile Rehabilitation Protocol, which is used by Urology clinics around the country. He has also been featured in numerous articles and as a guest on many webinars and podcasts.    Links from this episode Revelation Pharma Website https://revelationpharma.com/ Penile Rehab Protocol Website Penilerehabprotocol.com ConsultRX Website https://revconsultrx.com/    Learn more about the protocol on YouTube https://youtu.be/__ibcRJup48?si=3ogFWKw_Fy29BYuB  YouTube Video (Men's Sexual Health Overview with Pharmacist Greg McKettrick) Greg on LinkedIn https://www.linkedin.com/in/greg-mckettrick-a21404163/  Greg's email Greg@revelationpharma.com Greg's phone number 704-883-2895 Zero Prostate Cancer https://zerocancer.org/    Kim's websites and social media links: ✅ Business website https://www.thepharmacistsvoice.com ✅ The Pharmacist's Voice ® Podcast https://www.thepharmacistsvoice.com/podcast ✅ The Perrysburg Podcast (service project/hobby podcast) www.perrysburgpodcast.com  ✅ Pronounce Drug Names Like a Pro © Online Course https://www.kimnewlove.com  ✅ Self-paced, online podcast-planning Course https://www.kimnewlove.com  ✅ FREE eBook and audiobook about podcasting https://www.kimnewlove.com/podcasting  ✅ LinkedIn https://www.linkedin.com/in/kimnewlove ✅ Facebook https://www.facebook.com/kim.newlove.96 ✅ Twitter https://twitter.com/KimNewloveVO ✅ Instagram https://www.instagram.com/kimnewlovevo/ ✅ YouTube https://www.youtube.com/channel/UCA3UyhNBi9CCqIMP8t1wRZQ ✅ ACX (Audiobook Narrator Profile) https://www.acx.com/narrator?p=A10FSORRTANJ4Z ✅ Start a podcast with the same coach who helped me get started (Dave Jackson from The School of Podcasting)! **Affiliate Link - NEW 9-8-23**      Thank you for listening to episode 303 of The Pharmacist's Voice ® Podcast.  If you know someone who would like this episode, please share it with them!

In this episode of the Bendy Bodies podcast, Dr. Linda Bluestein, the Hypermobility MD, has an in-depth conversation with Dr. Clair Francomano, a leading expert on connective tissue disorders and Chair of the Medical and Scientific Advisory Board for the Ehlers-Danlos Society. Dr. Francomano shares her insights on diagnosing hypermobile Ehlers-Danlos Syndrome (hEDS) versus hypermobility spectrum disorders (HSD), the current state of genetic testing, and emerging biomarkers (are we close?) that could revolutionize hEDS diagnosis. She discusses the potential connections between EDS, mast cell activation syndrome (MCAS), and postural orthostatic tachycardia syndrome (POTS), offering advice for patients navigating this complex landscape. With updates from ongoing research, this episode is essential listening for those with EDS or related conditions. Takeaways: Differences Between hEDS and HSD: Dr. Francomano explains the nuanced distinctions between hypermobile EDS (hEDS) and hypermobility spectrum disorders (HSD), noting that these categories may overlap more than previously thought and might benefit from unified diagnostic criteria in the future. Genetic Testing Red Flags: While genetic testing can be useful, Dr. Francomano highlights specific “red flags” in family history or personal health that should prompt a referral to a geneticist for further investigation. Current Limitations of Genetic Testing for hEDS: Unlike other types of EDS, hEDS currently has no identified genetic markers, meaning diagnosis relies on clinical criteria rather than genetic testing alone. Emerging Biomarkers Show Promise: New studies, such as those exploring fibronectin and calocrine, suggest potential biomarkers for hEDS and HSD, which could transform diagnosis and treatment in the future. Holistic Approach to Comorbidities: Dr. Francomano discusses how hEDS often presents with comorbidities like POTS and mast cell activation syndrome, recommending a comprehensive, multidisciplinary approach to manage these interconnected symptoms effectively. Connect with YOUR Bendy Specialist, Dr. Linda Bluestein, MD at https://www.hypermobilitymd.com/. Thank YOU so much for tuning in. We hope you found this episode informative, inspiring, useful, validating, and enjoyable. Join us on the next episode for YOUR time to level up your knowledge about hypermobility disorders and the people who have them. Join YOUR Bendy Bodies community at https://www.bendybodiespodcast.com/. Learn more about Human Content at http://www.human-content.com Podcast Advertising/Business Inquiries: sales@human-content.com YOUR bendy body is our highest priority! Learn about Dr. Clair Francomano Her Book: https://amzn.to/4e3eSaF Instagram: @dr.clairfrancomano Youtube: @DoctorClair Keep up to date with the HypermobilityMD: YouTube: youtube.com/@bendybodiespodcast Twitter: twitter.com/BluesteinLinda LinkedIn: linkedin.com/in/hypermobilitymd Facebook: facebook.com/BendyBodiesPodcast Blog: hypermobilitymd.com/blog Part of the Human Content Podcast Network Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of the Bendy Bodies podcast, Dr. Linda Bluestein, the Hypermobility MD, has an in-depth conversation with Dr. Clair Francomano, a leading expert on connective tissue disorders and Chair of the Medical and Scientific Advisory Board for the Ehlers-Danlos Society. Dr. Francomano shares her insights on diagnosing hypermobile Ehlers-Danlos Syndrome (hEDS) versus hypermobility spectrum disorders (HSD), the current state of genetic testing, and emerging biomarkers (are we close?) that could revolutionize hEDS diagnosis. She discusses the potential connections between EDS, mast cell activation syndrome (MCAS), and postural orthostatic tachycardia syndrome (POTS), offering advice for patients navigating this complex landscape. With updates from ongoing research, this episode is essential listening for those with EDS or related conditions. Takeaways: Differences Between hEDS and HSD: Dr. Francomano explains the nuanced distinctions between hypermobile EDS (hEDS) and hypermobility spectrum disorders (HSD), noting that these categories may overlap more than previously thought and might benefit from unified diagnostic criteria in the future. Genetic Testing Red Flags: While genetic testing can be useful, Dr. Francomano highlights specific “red flags” in family history or personal health that should prompt a referral to a geneticist for further investigation. Current Limitations of Genetic Testing for hEDS: Unlike other types of EDS, hEDS currently has no identified genetic markers, meaning diagnosis relies on clinical criteria rather than genetic testing alone. Emerging Biomarkers Show Promise: New studies, such as those exploring fibronectin and calocrine, suggest potential biomarkers for hEDS and HSD, which could transform diagnosis and treatment in the future. Holistic Approach to Comorbidities: Dr. Francomano discusses how hEDS often presents with comorbidities like POTS and mast cell activation syndrome, recommending a comprehensive, multidisciplinary approach to manage these interconnected symptoms effectively. Connect with YOUR Bendy Specialist, Dr. Linda Bluestein, MD at https://www.hypermobilitymd.com/. Thank YOU so much for tuning in. We hope you found this episode informative, inspiring, useful, validating, and enjoyable. Join us on the next episode for YOUR time to level up your knowledge about hypermobility disorders and the people who have them. Join YOUR Bendy Bodies community at https://www.bendybodiespodcast.com/. Learn more about Human Content at http://www.human-content.com Podcast Advertising/Business Inquiries: sales@human-content.com YOUR bendy body is our highest priority! Learn about Dr. Clair Francomano Her Book: https://amzn.to/4e3eSaF Instagram: @dr.clairfrancomano Youtube: @DoctorClair Keep up to date with the HypermobilityMD: YouTube: youtube.com/@bendybodiespodcast Twitter: twitter.com/BluesteinLinda LinkedIn: linkedin.com/in/hypermobilitymd Facebook: facebook.com/BendyBodiesPodcast Blog: hypermobilitymd.com/blog Part of the Human Content Podcast Network Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Integrative Cancer Solutions, we are joined by Professor Dr. Sarper Diler, a distinguished medical doctor and oncologist, to discuss his unique approach to cancer treatment through integrative oncology. Prof. Diler shares his personal cancer journey, highlighting his battle with a large kidney tumor, treated through a combination of traditional surgery and alternative methods, including radical nephrectomy and the Gonzalez protocol.Key Discussion Points:Personalized Cancer Treatment: Prof. Diler emphasizes the importance of tailoring treatments to the individual, including the integration of pancreatic enzymes, specific diets, and detoxification. He shares insights into the Gonzalez protocol, which combines these elements to help support the body's natural healing processes.The Role of Pancreatic Enzymes: Drawing on historical and modern applications, Prof. Diler explains how pancreatic enzymes are used in cancer treatment and their significance in improving patient outcomes.Prof. Diler's Cancer Journey: From the moment he was diagnosed with a kidney tumor, Prof. Diler's experience shaped his transition from conventional oncology to integrative methods. His personal treatment approach, involving both surgery and alternative therapies, demonstrates the power of holistic cancer care.Belief and Compliance: One of the key takeaways from Prof. Diler's experience is the critical role of patient belief and adherence to the treatment protocol. He stresses that success with the Gonzalez protocol requires full commitment and belief in the process.Advancements in Cancer Treatment: Prof. Diler also touches on emerging technologies in cancer care, such as the potential for using wearable devices to deliver pancreatic enzymes, a field being researched at the Orbital Institute.Success Stories: Prof. Diler shares powerful testimonials of patients who have followed the Gonzalez protocol and experienced improved energy, mood, and quality of life.Action Items:Explore the Gonzalez Protocol website to learn more about integrative cancer treatments.Explore the Ovital Institute to learn moreConclusion:Dr. Diller's insights into integrative oncology offer hope and valuable knowledge for cancer patients and their families. Tune in to learn more about how personalized treatments can improve both quality of life and health outcomes.Be sure to visit the Karlfeldt Center website for more resources and information on future consultations.About Prof. Sarper Diler:He is the director of OVITAL Institute and serves as the Chair of the Scientific Advisory Board for the Nicholas Gonzalez Foundation in the US. He is highly active in numerous international scientific and patient-focused groups and committees.His previous roles include serving as the President of Myeloma Patients Europe (MPE), as a member of the European Cancer Organization Patient Advisory Committee (ECCO-PAC), the European Cancer Concord (ECC), and as Secretary General and Board Member of the Lymphoma Association (LC).Prof. Diler is a certified International Stem Cell Transplant Coordinator (CHTC) at the American National Donor Program (NMDP) and a specialist in Cancer Diet, Microbiome, and Heart Rate Variability, with certifications from Colorado Boulder and Arizona Universities, respectively. As an Integrative Oncologist, he holds memberships with SIO and BSIO. Additionally, he is a certified homeopath through the European Committee for Homeopathy (ECH) and the London College of Homeopathy (LCH).He has authored over 200 scientific articles and currently offers unique services worldwide under the umbrella of OVITAL Institute and OVITAL International Consultancy. His work also includes running preclinical and clinical trials focused on Cancer, Autonomic Nervous System clinical interferences, Epigenetics, Gut-Heart-Brain axis coherence, and Quantum diagnostics and treatments.----Grab my book A Better Way to Treat Cancer: A Comprehensive Guide to Understanding, Preventing and Most Effectively Treating Our Biggest Health Threat - https://www.amazon.com/dp/B0CM1KKD9X?ref_=pe_3052080_397514860 ----Integrative Cancer Solutions was created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com

In this episode, we're thrilled to welcome a very special guest, Lanning Ardente, the Co-Founder and CEO of Sorette—the new gold standard for motherhood products. Sorette not only offers a one-stop shop for safe and trusted products but also features their renowned Seal of Approval, developed by a team of leading toxicologists, thought partners, and their Scientific Advisory Board made up of OBGYNs, Dermatologists, Epidemiologists, Nutritionists, and experts in Women's Health.Lanning shares her journey from being a mom to creating Sorette, what inspired her to start this revolutionary brand, and how they developed their high standards to ensure that moms and families are surrounded by trusted products. Their approach allows moms to focus less on scrutinizing ingredient labels and more on what really matters—bonding with baby and taking care of themselves during this precious, transitional time.Shop now at https://shopsorette.com⭐️ Sorette has given our listeners an exclusive discount code. Use code: MOMCHAT15 to get 15% off your order.Make sure to also follow Sorette on Instagram: @shopsoretteJoin the official Mom Group Chat Facebook group: Mom Group Chat | FacebookKeep up with the Moms and join the conversation on our socials:Instagram: @‌momgroupchatTikTok: @‌momgroupchatQuestions/comments/need to vent? Email us at momgroupchat@gmail.com

In this episode, sociologist Brandon Vaidyanathan interviews MIT Physicist Dr. Alan Lightman about his spiritual materialism.Alan Lightman is an American physicist, writer, and social entrepreneur. He holds a PhD in physics from Caltech. He has served on the faculties of Harvard and the Massachusetts Institute of Technology (MIT) and was the first person at MIT to receive dual faculty appointments in science and in the humanities. He is currently professor of the practice of the humanities at MIT. Lightman is the recipient of six honorary doctoral degrees. He is the author of numerous books, both nonfiction and fiction, including Einstein's Dreams, an international bestseller, and The Diagnosis, a finalist for the National Book Award in fiction. His essays concern the intersection of science, culture, philosophy, and theology. Lightman is the host of the public television series “SEARCHING: Our Quest for Meaning in the Age of Science,” funded by the John Templeton Foundation. In 2005, Lightman founded Harpswell, a nonprofit organization devoted to empowering young women leaders in Southeast Asia, and he has served as chair of its board. In August 2023, Lightman was appointed a member of the United Nations' Scientific Advisory Board. His latest book is The Transcendent Brain: Spirituality in the Age of Science (2023).In this second part of our conversation, we talk about:The limits of scientific inquiryHow to interpret spiritual experiencesThe concept of creative transcendenceWhy spirituality matters for us allAlan's humanitarian work To learn more about Alan and his work:LinkedIn: https://www.linkedin.com/in/alan-lightman-6bb7191b6Website: https://cmsw.mit.edu/alan-lightman/Email: lightman@mit.eduBooks: https://www.amazon.com/stores/author/B000APY6Q4Scientific Publications: https://cmsw.mit.edu/alan-lightman/#SCIENTIFIC%20PUBLICATIONSHarpswell Organization: https://harpswell.org/ This episode is sponsored by:John Templeton Foundation (https://www.templeton.org/) andTempleton Religion Trust (https://templetonreligiontrust.org/)Support the show

In this episode, sociologist Brandon Vaidyanathan interviews MIT Physicist Dr. Alan Lightman about his spiritual materialism.Alan Lightman is an American physicist, writer, and social entrepreneur. He holds a PhD in physics from Caltech. He has served on the faculties of Harvard and the Massachusetts Institute of Technology (MIT) and was the first person at MIT to receive dual faculty appointments in science and in the humanities. He is currently professor of the practice of the humanities at MIT. Lightman is the recipient of six honorary doctoral degrees. He is the author of numerous books, both nonfiction and fiction, including Einstein's Dreams, an international bestseller, and The Diagnosis, a finalist for the National Book Award in fiction. His essays concern the intersection of science, culture, philosophy, and theology. Lightman is the host of the public television series “SEARCHING: Our Quest for Meaning in the Age of Science,” funded by the John Templeton Foundation. In 2005, Lightman founded Harpswell, a nonprofit organization devoted to empowering young women leaders in Southeast Asia, and he has served as chair of its board. In August 2023, Lightman was appointed a member of the United Nations' Scientific Advisory Board. His latest book is The Transcendent Brain: Spirituality in the Age of Science (2023).In this first part of our conversation, we talk about:Balancing interests in art and science from a young ageThe role of beauty in scientific discoveryAlan's concept of spiritual materialismTranscendence and the Hindu concept of "darshan"To learn more about Adam and his work:LinkedIn: https://www.linkedin.com/in/alan-lightman-6bb7191b6Website: https://cmsw.mit.edu/alan-lightman/Email: lightman@mit.eduBooks: https://www.amazon.com/stores/author/B000APY6Q4Scientific Publications: https://cmsw.mit.edu/alan-lightman/#SCIENTIFIC%20PUBLICATIONSHarpswell Organization: https://harpswell.org/ This episode is sponsored by:John Templeton Foundation (https://www.templeton.org/) andTempleton Religion Trust (https://templetonreligiontrust.org/)Support the show

Today on American Glutton Ethan welcomes Dr. Biamonte, author of The Candida Chronicles. Dr. Biamonte is a NY State certified Clinical Nutritionist, a professional member of the International and American Association of Clinical Nutritionists, The American College of Nutrition, and is a member of the Scientific Advisory Board for the Clinical Nutrition Certification Board. SHOW HIGHLIGHTS(00:00) Episode Intro(00:38) Understanding Candida Overgrowth and Treatment(15:38) Navigating Personalized Supplement Recommendations(22:19) Exploring Metabolism, Candida, and Seed Oils(32:23) The Dangers of Polyunsaturated Oils(44:29) GMO Foods and Thyroid Dangers(54:14) Biochemical Individuality and Personalized Nutrition Hosted on Acast. See acast.com/privacy for more information.

In this video, Riley interviews Jini Glaros, the Chief Science Officer (CSO) at Modern Canna, about groundbreaking research on the relationship between water activity and moisture content in cannabis. Whether you're part of an MSO, a home grower, or just passionate about cannabis science, understanding how these factors influence product quality, shelf life, and data accuracy is essential. Watch as Jini shares key insights from her experiments and discusses how this information can help improve industry standards and reporting practices. Don't miss out on these valuable takeaways that can elevate your knowledge and practices in cannabis cultivation and quality control.

Dr Kristal has not only lost more than what she now weighs….but using her story she has become a light to others who feel broken in their health. Let's learn how to get Back to the Basics with great nutrition and the drop system.   ---  UPGRADE YOUR BRAINUNLEASH AND USE YOUR UNIQUENESS ⁠   https://braingym.fitness/⁠    ------------    Speaking Podcast Social Media / Coaching My Other Podcasts    ⁠⁠⁠https://roycoughlan.com/⁠⁠   Find the Products mentioned in this Episode or Join the Business   https://partnerco.world/ ------------------    About my Guest Dr Kristal Vance:   Dr Kristal lives in the US - Orlando, FL area. Many may know her from founding the Circle of Health where she began that community after her own journey with the hormone body balance drops. After 25 years of working with patients she had lost herself and her health. She experienced autoimmune issues and her hormones were wrecked! Dr Kristal has not only lost more than what she now weighs….but using her story she has become a light to others who feel broken in their health. Let's learn how to get Back to the Basics with great nutrition and the drop system. Dr Kristal sits on the Wellness Council and a Member of the Partnerco North America partners council.   What we Discussed:  - Who is Dr. Kristal Vance- Her own Health Issues when Younger (3 mins)   - How the Products helped our friend Bill Chaffee get off an insulin pump (6:15 mins)   - The Industry is Broken (8 mins)   - The 2 Founders of Partner Co (9 mins to18:55mins)   - Tahetian Noni Jucie (11 mins)   - The got 14 legacy Companies (16:30 mins)   - The have a Scientific Advisory Board (17:20 mins)   - Why this Noni is so beneficial (19:40 mins)   - How the Drops helped her Father David Vance (21 mins)   - The Dangers of Sugar (23:15 mins)- I lost me (24 mins)   - Why Dieting did not seem right (25:30 mins)   - 6 yrs out and she kept the Weight off (27:30 mins)   - Mom was on 19 Medications and now just 4 (27:45 mins)   - They created a Community for Health support (29:50 mins)   - My Food Ant Test (31:30 mins)   - If only our Bodies had a Low Battery display (33 mins)   - Over 100 Products that have has proper testing(34:30 mins)    - Low Entry Point to the Business $29.95 (36 mins)     Find the Products or Start in the Business :    https://partnerco.world/  ------------------------------   Help Support the Podcast by visiting my Store, Making a Donation or Supporting my Sponsors    http://meditationpodcast.org/   Our Facebook Group can be found at ⁠   https://www.facebook.com/meditationpodcast.org

Dr Kristal has not only lost more than what she now weighs….but using her story she has become a light to others who feel broken in their health. Let's learn how to get Back to the Basics with great nutrition and the drop system.   ---  UPGRADE YOUR BRAINUNLEASH AND USE YOUR UNIQUENESS ⁠   https://braingym.fitness/⁠    ------------    Speaking Podcast Social Media / Coaching My Other Podcasts    ⁠⁠⁠https://roycoughlan.com/⁠⁠   Find the Products mentioned in this Episode or Join the Business   https://partnerco.world/ ------------------    About my Guest Dr Kristal Vance:   Dr Kristal lives in the US - Orlando, FL area. Many may know her from founding the Circle of Health where she began that community after her own journey with the hormone body balance drops. After 25 years of working with patients she had lost herself and her health. She experienced autoimmune issues and her hormones were wrecked! Dr Kristal has not only lost more than what she now weighs….but using her story she has become a light to others who feel broken in their health. Let's learn how to get Back to the Basics with great nutrition and the drop system. Dr Kristal sits on the Wellness Council and a Member of the Partnerco North America partners council.   What we Discussed:  - Who is Dr. Kristal Vance- Her own Health Issues when Younger (3 mins)   - How the Products helped our friend Bill Chaffee get off an insulin pump (6:15 mins)   - The Industry is Broken (8 mins)   - The 2 Founders of Partner Co (9 mins to18:55mins)   - Tahetian Noni Jucie (11 mins)   - The got 14 legacy Companies (16:30 mins)   - The have a Scientific Advisory Board (17:20 mins)   - Why this Noni is so beneficial (19:40 mins)   - How the Drops helped her Father David Vance (21 mins)   - The Dangers of Sugar (23:15 mins)- I lost me (24 mins)   - Why Dieting did not seem right (25:30 mins)   - 6 yrs out and she kept the Weight off (27:30 mins)   - Mom was on 19 Medications and now just 4 (27:45 mins)   - They created a Community for Health support (29:50 mins)   - My Food Ant Test (31:30 mins)   - If only our Bodies had a Low Battery display (33 mins)   - Over 100 Products that have has proper testing(34:30 mins)    - Low Entry Point to the Business $29.95 (36 mins)     Find the Products or Start in the Business :    https://partnerco.world/  ------------------------------   Help Support the Podcast by visiting my Store, Making a Donation or Supporting my Sponsors    https://www.awakeningpodcast.org/   Our Facebook Group can be found at ⁠   https://www.facebook.com/royawakening

Dr Kristal has not only lost more than what she now weighs….but using her story she has become a light to others who feel broken in their health. Let's learn how to get Back to the Basics with great nutrition and the drop system. ---  UPGRADE YOUR BRAINUNLEASH AND USE YOUR UNIQUENESS ⁠ https://braingym.fitness/⁠  ------------  Speaking Podcast Social Media / Coaching My Other Podcasts  ⁠⁠⁠https://roycoughlan.com/⁠⁠ Find the Products mentioned in this Episode or Join the Business https://partnerco.world/ ------------------  About my Guest Dr Kristal Vance: Dr Kristal lives in the US - Orlando, FL area. Many may know her from founding the Circle of Health where she began that community after her own journey with the hormone body balance drops. After 25 years of working with patients she had lost herself and her health. She experienced autoimmune issues and her hormones were wrecked! Dr Kristal has not only lost more than what she now weighs….but using her story she has become a light to others who feel broken in their health. Let's learn how to get Back to the Basics with great nutrition and the drop system. Dr Kristal sits on the Wellness Council and a Member of the Partnerco North America partners council. What we Discussed:  - Who is Dr. Kristal Vance- Her own Health Issues when Younger (3 mins) - How the Products helped our friend Bill Chaffee get off an insulin pump (6:15 mins) - The Industry is Broken (8 mins) - The 2 Founders of Partner Co (9 mins to18:55mins) - Tahetian Noni Jucie (11 mins) - The got 14 legacy Companies (16:30 mins) - The have a Scientific Advisory Board (17:20 mins) - Why this Noni is so beneficial (19:40 mins) - How the Drops helped her Father David Vance (21 mins) - The Dangers of Sugar (23:15 mins)- I lost me (24 mins) - Why Dieting did not seem right (25:30 mins) - 6 yrs out and she kept the Weight off (27:30 mins) - Mom was on 19 Medications and now just 4 (27:45 mins) - They created a Community for Health support (29:50 mins) - My Food Ant Test (31:30 mins) - If only our Bodies had a Low Battery display (33 mins) - Over 100 Products that have has proper testing(34:30 mins)  - Low Entry Point to the Business $29.95 (36 mins) Find the Products or Start in the Business :  https://partnerco.world/  ------------------------------ Help Support the Podcast by visiting my Store, Making a Donation or Supporting my Sponsors  ⁠https://www.speakingpodcast.com/⁠   Our Facebook Group can be found at ⁠ https://www.facebook.com/speakingpodcast⁠

Share this episode: https://www.samharris.org/podcasts/making-sense-episodes/379-regulating-artificial-intelligence Sam Harris speaks with Yoshua Bengio and Scott Wiener about AI risk and the new bill introduced in California intended to mitigate it. They discuss the controversy over regulating AI and the assumptions that lead people to discount the danger of an AI arms race. Yoshua Bengio is full professor at Université de Montréal and the Founder and Scientific Director of Mila - Quebec AI Institute. Considered one of the world’s leaders in artificial intelligence and deep learning, he is the recipient of the 2018 A.M. Turing Award with Geoffrey Hinton and Yann LeCun, known as the Nobel Prize of computing. He is a Canada CIFAR AI Chair, a member of the UN’s Scientific Advisory Board for Independent Advice on Breakthroughs in Science and Technology, and Chair of the International Scientific Report on the Safety of Advanced AI. Website: https://yoshuabengio.org/ Scott Wiener has represented San Francisco in the California Senate since 2016. He recently introduced SB 1047, a bill aiming to reduce the risks of frontier models of AI. He has also authored landmark laws to, among other things, streamline the permitting of new homes, require insurance plans to cover mental health care, guarantee net neutrality, eliminate mandatory minimums in sentencing, require billion-dollar corporations to disclose their climate emissions, and declare California a sanctuary state for LGBTQ youth. He has lived in San Francisco's historically LGBTQ Castro neighborhood since 1997. Twitter: @Scott_Wiener Learning how to train your mind is the single greatest investment you can make in life. That’s why Sam Harris created the Waking Up app. From rational mindfulness practice to lessons on some of life’s most important topics, join Sam as he demystifies the practice of meditation and explores the theory behind it.

Michael Biamonte is the founder of the Biamonte Center for Clinical Nutrition. He is a co-creator of BioCybernetics, which is an unprecedented computer software program that is able to study blood work, mineral tests and many other lab tests to determine exactly where your body is imbalanced initially designed for aerospace purposes.  As a practitioner for over 30 years, he is dedicated to improving the lives of his patients and helping them get back to living.  He holds a Doctorate of Nutripathy and is a New York State certified Clinical Nutritionist. He is a professional member of the International and American Association of Clinical Nutritionists, The American College of Nutrition and is a member of the Scientific Advisory Board for the Clinical Nutrition Certification Board. He is listed in “The Directory of Distinguished Americans'' for his research in Nutrition and Physiology. Buy Michael's Book "The Candida Chronicles" Here Visit The Biamonte Center for Clinical Nutrition Here

Dr. Frank Wilczek is the newly announced recipient of the 2022 Templeton Prize, which, valued at over $1.4 million, is one of the world's largest annual individual awards. Dr. Wilczek is celebrated for his investigations into the fundamental laws of nature that have transformed our understanding of the forces that govern our universe. In this video, Dr. Wilczek explores the question, ‘does the world embody beautiful ideas?' through science and humankind's relationship to (and love for) symmetry. "We can look at the record of what people have found beautiful, what they were hoping for in their understanding of the world with what the remarkable understanding of the world we've achieved in recent years looks like. And we can therefore frame a meaningful discussion and a meaningful question, a meaningful meditation, on the issue.” The Templeton Prize was established by the late global investor and philanthropist Sir John Templeton. It is given to honor those who harness the power of the sciences to explore the deepest questions of the universe and humankind's place and purpose within it. -------------------------------------------------------------- About Frank Wilczek: Frank Wilczek is an American theoretical physicist, mathematician and a Nobel laureate. He is currently the Herman Feshbach Professor of Physics at the Massachusetts Institute of Technology (MIT). Wilczek, along with David Gross and H. David Politzer, was awarded the Nobel Prize in Physics in 2004 for their discovery of asymptotic freedom in the theory of the strong interaction. He is on the Scientific Advisory Board for the Future of Life Institute. His new book is titled A Beautiful Question: Finding Nature's Deep Design. ---------------------------------------------------------------------------------- About The Well Do we inhabit a multiverse? Do we have free will? What is love? Is evolution directional? There are no simple answers to life's biggest questions, and that's why they're the questions occupying the world's brightest minds. So what do they think? How is the power of science advancing understanding? How are philosophers and theologians tackling these fascinating questions? Let's dive into The Well. ---------------------------------------------------------------------------------- Learn more about your ad choices. Visit megaphone.fm/adchoices

Michael Biamonte is the founder of the Biamonte Center for Clinical Nutrition. He is a co-creator of BioCybernetics, which is an unprecedented computer software program that is able to study blood work, mineral tests and many other lab tests to determine exactly where your body is imbalanced initially designed for aerospace purposes.  As a practitioner for over 30 years, he is dedicated to improving the lives of his patients and helping them get back to living.  He holds a Doctorate of Nutripathy and is a New York State certified Clinical Nutritionist. He is a professional member of the International and American Association of Clinical Nutritionists, The American College of Nutrition and is a member of the Scientific Advisory Board for the Clinical Nutrition Certification Board. He is listed in “The Directory of Distinguished Americans'' for his research in Nutrition and Physiology. Buy Michael's Book "The Candida Chronicles" Here Visit The Biamonte Center for Clinical Nutrition Here

In episode 167, I discuss candida infections with Dr. Michael Biamonte. Topics covered in this episode include: What is candida? What allows candida to be overgrown? The challenges caused by candida overgrowth Foods that aggravate candida-related symptoms The connection between thyroid conditions and candida And more... Michael Biamonte is the founder of the Biamonte Center for Clinical Nutrition. He is a co-creator of BioCybernetics, which is an unprecedented computer software program that is able to study blood work, mineral tests and many other lab tests to determine exactly where your body is imbalanced initially designed for aerospace purposes. As a practitioner for over 30 years, he is dedicated to improving the lives of his patients and helping them get back to living. He holds a Doctorate of Nutripathy and is a certified clinical nutritionist in New York State. He is a professional member of the International and American Association of Clinical Nutritionists, The American College of Nutrition and is a member of the Scientific Advisory Board for the Clinical Nutrition Certification Board. He is listed in “The Directory of Distinguished Americans'' for his research in Nutrition and Physiology. Facebook - https://www.facebook.com/The-Biamonte-Center-241435772676317/ YouTube - https://www.youtube.com/channel/UCiss7csT6pBnPAyeNA5AbDQ www.health-truth.com

Heal your gut in 3 Steps with guest expert Dr. Will BulsiewiczIs your gut giving you trouble? Do you have food sensitivities? Do you just want to feel even better? Ready to find out exactly how your microbiome can function FOR you and how can YOU make it optimal with three small steps ?Listen in, as you'll discover how many of your daily symptoms are likely connected to gut health and what to do about it!Be sure to check out this episode with such an incredible gut health expert, NY Times bestselling author and gastroenterologist, Dr. Will Bulsiewicz!In this episode, you will learn: The Role of the Gut Microbiome: Understanding how gut bacteria influence health and disease.Three Steps To Health Your Gut: Cut out, assess and re-introduce and what that all means.Fiber and Gut Health: The impact of dietary fiber on gut function and microbiome diversity.Food Sensitivities and Intolerances: Identifying and managing food sensitivities for improved gut health.The Importance of Plant Diversity: How consuming a variety of plant foods supports a healthy gut microbiome.Gut Health and Mental Well-being: Exploring the connection between gut health and mental health conditions like anxiety and depression.Holistic Approaches to Gut Healing: Integrating diet, lifestyle, and emotional well-being for comprehensive gut health.The Effect of Processed Foods on Gut Health: Understanding how ultra-processed foods impact the gut microbiome.The Growth Mindset in Health: Applying the growth mindset concept to personal health and wellness journeys.Personalized Nutrition: Tailoring dietary recommendations to individual gut microbiome profiles and health needs.Practical Steps for Improving Gut Health: Actionable strategies for enhancing gut health through diet and lifestyle changes.... And much moreABOUT: GUEST EXPERT DR. WILL BULSIEWICZRENOWN GUT HEALTH EXPERT, GASTROENTEROLOGIST, BESTSELLING AUTHORDr. Will Bulsiewicz ("Dr. B") is an award winning gastroenterologist, internationally recognized gut health expert and the New York Times, Publishers Weekly, USA Today, and Indie Bound-bestselling author of Fiber Fueled and The Fiber Fueled Cookbook.With a passion for plants and helping people, he sits on the Scientific Advisory Board of ZOE, has authored more than twenty articles published in peer-reviewed scientific journals, has given more than forty presentations at national meetings, presented to Congress and the USDA, and has taught over 10,000 students how to heal and optimize their gut health.He completed a bachelor's degree from Vanderbilt University, a medical degree from Georgetown University, and a master's in clinical investigation from Northwestern University. Dr. B was the chief medical resident at Northwestern and the chief gastroenterology fellow at The University of North Carolina, and received the highest award given by both his residency and fellowship.Dr. B completed an epidemiology fellowship on a grant from the National Institutes of Health at UNC's prestigious Gillings School of Global Public Health.He lives in Charleston, South Carolina with his wife and children.You'll find him on:Instagram: @theguthealthmdFacebook:...

In this episode, I speak with Dr. Bill Campbell, a member of our Scientific Advisory Board. We explore the critical importance of whole food nutrition for fat loss and emphasize the vital role of protein in your diet.     We explain the significant differences between processed and whole foods, and discuss how making healthier food choices can dramatically improve your body composition, metabolism, and energy levels. We share eye-opening studies and practical tips to help you follow a whole food-based meal plan.   Dr. Campbell and I also highlight the necessity of protein for muscle building, while providing practical advice on daily protein intake and its distribution throughout the day. We also discuss the benefits of high-quality protein sources, both animal-based and plant-based, and how a higher protein diet can support your fat loss goals by increasing satiety. Our conversation is packed with actionable insights that can help you optimize your nutrition. Sign up for the Summer Slimdown: https://summerslimdown.fasterwaytofatloss.com/   Don't forget to check out our merch, supplements and other great deals: https://fasterwayshop.com/   Subscribe: youtube.com/FASTerWaytoFatLoss   Follow us on Instagram: Amanda Tress: https://www.instagram.com/amandatress FASTer Way to Fat Loss: https://www.instagram.com/fasterwaytofatloss Dr. Bill Campbell: https://www.instagram.com/billcampbellphd/  

As a brain tumor survivor and the youngest winner of NYU Stern's business plan competition, Chris Mirabile is known for beating the odds. Throughout his career, Chris has pursued a lifelong passion “health and wellness“ with an emphasis on avoiding disease, and extending his healthy lifespan. According to independently verified third-party epigenetic, metabolomic, telomere, and physiological tests, he was able to reduce his biological age by 37% and his pace of aging by 31%. Now approaching a chronological age of 40, Chris' biology is by most accounts that of someone in his mid-twenties. In following his life-long passion and after more than a decade of research and experimentation, Chris founded NOVOS, the first nutraceutical company that targets the 12 biological causes of aging to increase longevity. NOVOS includes a Scientific Advisory Board of six of the world's top biologists and geneticists who study aging from Harvard, MIT, The Salk Institute, and more. With NOVOS, Chris created much more than a supplement company, he built the leading consumer biotech platform that leverages the latest science to help people take control of their healthspans and lifespans. NOVOS is a Public Benefit Corporation (PBC).

Join us for an exclusive event as we unveil our groundbreaking Untypical™ Personal Care Collection, set to revolutionize the personal care industry. Hosted by Katherine Garfield and featuring Dr. Giselle Batcheller, a renowned expert and member of our Scientific Advisory Board, this is a rare opportunity to gain deep insights into our newest product line.Discover how Untypical™ Lift, Hydrate, and Shield are redefining beauty standards with innovative formulations tailored to diverse personal care needs. Learn about the cutting-edge science behind our products, including our revolutionary SomaTech® technology, and explore the transformative potential of ingredients like Reproage™ and hyaluronic acid.Whether you're a personal care enthusiast, an industry professional, or simply curious about the future of personal care, this event promises invaluable knowledge and inspiration. Don't miss your chance to be part of this extraordinary journey toward healthier, more radiant skin.

Dr. Deborah Rozman, President and co-CEO of HeartMath Inc., has been a key leader since 1991, advancing the mission to create a more resilient and heart-centered world. HeartMath's programs offer scientifically validated techniques for emotional self-regulation and energy management, promoting health, resilience, and enhanced intuition. Dr. Rozman co-authored the Transforming book series and "Heart Intelligence," emphasizing heart-based guidance for effective decision-making. As a spokesperson, she advocates for heart intelligence in media, interviews, and keynote addresses, addressing personal, social, and global well-being. Dr. Rozman also contributes to the Advisory Board of the Transformative Technology Lab and HeartMath Institute's Scientific Advisory Board and Global Coherence Initiative Steering Committee. She is known for her role in developing award-winning technologies like emWave® and Inner Balance™ for heart-brain coherence.SHOW SUMMARYIn this episode of the Selling from the Heart Podcast, Larry Levine and Darrell Amy dive into the transformative power of heart-based selling with special guest Deborah Rozman, President and CEO of HeartMath Institute. They explore how aligning the heart, mind, and emotions can revolutionize your sales approach, boost performance, and reduce stress. Deborah shares insights from HeartMath's extensive research and introduces practical techniques to achieve heart coherence, making every sales interaction more genuine and impactful.KEY TAKEAWAYSHeart-Based Selling: Understand the importance of authenticity and trust in sales and how connecting through the heart can enhance relationships with customers.The Science of Coherence: Learn about the scientific basis of heart coherence and its impact on the brain, emotions, and overall well-being.Practical Techniques: Discover a simple yet powerful technique to achieve heart coherence, which can be used before, during, and after-sales interactions to maintain focus and reduce stress.Real-World Applications: Hear how sales professionals can integrate heart-focused breathing into their daily routines to improve their interactions and overall sales performance.Emotional and Physiological Benefits: Explore the broader benefits of heart coherence, including improved sleep, reduced anxiety, and better decision-making.QUOTES"Simplicity is crunched complexity. If things weren't simple, we'd never get there.""Life is fulfilling when you connect in the heart with whomever you're interacting with.""When you establish heart resonance, you intuitively know what to share and how to position what you have to sell.""Creating a coherent, resonant vibration by heart-focused breathing with love, care, kindness, or appreciation establishes resonance with the other person.""Incoherence is an expensive habit. Anxiety and stress can cost you dearly in sales performance."Learn more about Deborah Rozman: LinkedIn: https://www.linkedin.com/in/deborahrozman/Learn more about Darrell and Larry: Darrell's LinkedIn: https://www.linkedin.com/in/darrellamy/Larry's LinkedIn: https://www.linkedin.com/in/larrylevine1992/Website: https://www.sellingfromtheheart.net/Get the New Book That Will Help You Sell More... Without Destroying Your Relationships and Reputationhttps://sellinginaposttrustworld.com/home-prereleasePlease visit Barnes & Nobles to order your copy of the rerelease of the Selling from the Heart book.https://www.barnesandnoble.com/w/selling-from-the-heart-larry-levine/1130142818SUBSCRIBE to our YOUTUBE CHANNEL!https://www.youtube.com/c/sellingfromtheheart/Please visit WHY INSTITUTE:https://whyinstitute.com/Please go to WORK BETTER NOW:https://www.workbetternow.com/Click for your Daily Dose of Inspiration:https://www.sellingfromtheheart.net/daily

Dr. Monnica Williams is a professor at the University of Ottawa, where she holds the Canada Research Chair in mental health disparities. Her research is focused on mental health, race, racism and novel approaches to treatment. In this conversation, she is sharing about her research and tips for healing racial trauma based on the latest research.She also offers a call to action for players in the psychedelic space to improve diversity at all levels. We also discuss what a culturally informed psychedelic experience looks like, and what to look for in a guide if you're looking to heal racial trauma. This conversation offers support and hope for those who have been harmed by racial trauma. It also offers insights and language for those who aspire to be allies.Dr. Monnica T. Williams is a board-certified licensed clinical psychologist and Professor at the University of Ottawa in the School of Psychology, where she is the Canada Research Chair in Mental Health Disparities. She is also the Clinical Director of the Behavioral Wellness Clinics in Connecticut and Ottawa, where she provides supervision and training to clinicians for empirically-supported treatments. Prior to her move to Canada, Dr. Williams was on the faculty of the University of Pennsylvania Medical School (2007-2011); the University of Louisville in Psychological and Brain Sciences (2011-2016), where she served as the Director of the Center for Mental Health Disparities; and the University of Connecticut (2016-2019), where she had appointments in both Psychological Science and Psychiatry. Dr. Williams' research focuses on BIPOC mental health, culture, and psychopathology, and she has published over 200 scientific articles on these topics. Current projects include the assessment of race-based trauma, barriers to treatment in OCD, improving cultural competence in the delivery of mental health care services, and interventions to reduce racism. This includes prior work as a PI in a multisite study of MDMA-assisted psychotherapy for PTSD for people of color. She also gives diversity trainings nationally for clinical psychology programs, scientific conferences, and community organizations.Through the Kentucky Psychological Association (KPA), Dr. Williams served as the diversity delegate to Washington DC for the American Psychological Association (APA) State Leadership Conference for two consecutive years. She has served as the African American SIG leader for Association of Behavioral and Cognitive Therapies (ABCT), and currently is Chair of their Academic Training & Education Standards (ATES). She serves as an Associate Editor of Behavior Therapy. She also serves on the editorial board of Cognitive Behaviour Therapy, Canadian Psychology, International Journal of Mental Health, Journal of Psychedelic Studies, the Journal of Obsessive Compulsive and Related Disorders and the Cognitive Behavioural Therapist. She is a member of the Scientific Advisory Board of the International OCD Foundation and co-founded their Diversity Council. Her work has been featured in all major US and Canadian media outlets, including NPR, CBS, CTV, Huffington Post, and the New York Times.Topics Covered:What is racial trauma?Tools and research approaches that are applied to understand racial traumaTreatments developed for racial trauma by Dr. Williams, including psychedelicsCommunity and group work versus individual treatment for racial traumaDr. Williams' psychedelics for racial trauma research findingsIdeal set and setting when using psychedelics for healing racial traumaHow to vet your psychedelic guide for this workA culturally informed psychedelic experienceIntegrating a psychedelic experience when healing racial traumaIntentional steps the psychedelic space can take to diversifyShow Links:Apply for 1:1 Coaching with LanaWhere to find Dr. Monnica Williams:https://www.instagram.com/drmonnica/www.monnicawilliams.comDeliberate Practice in Psychedelic Assisted Therapy [book]Support Dr. Williams' research at mentalhealthdisparities.org Want more Modern Psychedelics?Instagram | YouTube | Web | Facebook Inspired to transform your life from the inside out, and integrate higher consciousness in your day to day life?Explore 1:1 Coaching with Lana or Apply Now This episode was produced in collaboration with FWI Media. Check out their beautiful work! Please support the show and leave a review if this episode sparked something within. FREEBIES to support your journey DISCLAIMER: Modern Psychedelics does not endorse or support the illegal consumption of any substances. This show is meant for entertainment purposes only. Modern Psychedelics does not sell or promote the sale of any illegal substances. The thoughts, views and opinions on this show should not be taken as life advice, medicinal advice, or therapeutic guidance.

In this episode of Exploring the Marketplace, Shawn Bolz and Bob Hasson sit down with Dr. Lee Cowden. W. Lee Cowden, MD, MD(H), is Chairman of the Scientific Advisory Board & Professor of the Academy of Comprehensive Integrative Medicine. He has been a USA board-certified cardiologist & internist and a licensed homeopathic medical doctor, but recently retired from patient care & is now teaching full-time. He has been studying integrative medicine since he was at the University of Texas Medical School at Houston in 1975-78. He has co-authored 6 books & is internationally known for his knowledge and skill in practicing & teaching integrative medicine. He has pioneered successful treatments for cancer, Lyme disease, atherosclerosis, cardiomyopathy, various neurological conditions, silicone implant disease and other illnesses, but he gives credit to God, Jesus and the Holy Spirit as the ultimate source of all healing. In this episode, Dr Lee Cowden discusses pressing topics such as job loss, layoffs, and finding encouragement through faith during challenging times. Dr. Cowden shares his insights and powerful words of knowledge he received that have empowered individuals to overcome seemingly impossible health conditions. Join us as we delve into Dr. Cowden's unique perspective and explore how faith can provide strength and resilience in the face of adversity. Discover powerful strategies for navigating uncertainty and finding hope in the midst of life's storms.Come join me on my Social Media: Facebook: ShawnbolzTwitter: ShawnBolzInstagram: ShawnBolzTikTok: ShawnBolzYouTube: ShawnBolzofficialTake a class or attend an event at our Spiritual Growth Academy: Our 4 week classes and monthly events are designed to do the heavy lifting in your spiritual growth journey. Learn how to hear from God, stay spiritually healthy, and impact the world around you: https://bit.ly/3B2luDRTake a read: Translating God - Hearing God's voice for yourself and the world around you https://bit.ly/3RU2X3FEncounter - A spiritual encounter that will shape your faith https://bit.ly/3tNAW4YThrough the Eyes of Love - http://bit.ly/2pitHTbWired to Hear - Hearing God's voice for your place of career and influence https://bit.ly/3kLsMn9Growing Up With God - Chapter book and kids curriculum https://bit.ly/3eDRF5aKeys to Heaven's Economy - Understanding the resources for your destiny: https://bit.ly/3TZAc7uEmail My Assistant: assistant@bolzministries.comOur resources: resources@bolzministries.comOur office: info@bolzministries.com

Welcome to Protecting Your Nest with Dr. Tony Hampton. Dr. Michael Biamonte is the founder of the Biamonte Center for Clinical Nutrition. He is a co creator of BioCybernetics, which is an unprecedented computer software program that is able to study blood work, mineral tests and many other lab tests to determine exactly where your body is imbalanced. He holds a Doctorate of Nutripathy and is a New York State certified Clinical Nutritionist. He is a professional member of the International and American Association of Clinical Nutritionists, The American College of Nutrition and is a member of the Scientific Advisory Board for the Clinical Nutrition Certification Board. He is listed in “The Directory of Distinguished Americans” for his research in Nutrition and Physiology. In this discussion, Drs. Tony and Michael talk about: (02:32) Why Dr. Michael chose to focus on nutrition and supplementation (05:55) The future of genetic and functional testing in patient care (09:13) How functional testing for nutritional deficiencies in a given person works (15:50) How the average person can know if they are taking the right supplements and how your hair might hold the key to answering this question (27:30) Tips for people seeking to heal from Candida and Hashimoto's (33:07) Dietary treatments for Candida (34:17) How blood type plays a role in choosing the right diet for you (39:36) Why people should not be too cavalier when it comes to taking vitamin supplements (43:25) How medications can lead to deficiencies in the body and make us sick (45:03) Problems with most vitamin supplements sold on the market (49:07) How supplements, medications, and diet impact the microbiome and how the microbiome then impacts the body (52:52) How Dr. Michael's approach is different from a more standard Western doctor (54:20) The importance of eating organic and non-GMO foods (54:56) How to find a good doctor who can test you accurately for nutritional deficiencies Thank you for listening to Protecting Your Nest. For additional resources and information, please see the links below.   Links:   Dr. Michael Biamonte: The Biamonte Center for Clinical Nutrition New Your City Candida Doctor New Your City Thyroid Doctor   Dr. Tony Hampton: Linktree Instagram Account LinkedIn Account Ritmos Negros Podcast Q Med Symposium for Metabolic Health Lectures How Waking Up Every Day at 4:30 Can Change Your Life

Dr. Michael Biamonte explains some of the basics between dieticians and clinical nutritionist. He shares the importance of testing for vitamin and mineral imbalances, as well as having someone knowledgeable enough to interpret the results. We talk about supplements and the role they play.Dr. Biamonte educates us on the damaging effects of candida overgrowth in the gut. Candida is disruptive to absorption and could be the internal cause of feeling bad all the time. He also sheds some light into the reaction our body has to pharmaceuticals.Dr. Michael Biamonte is the founder of the Biamonte Center for Clinical Nutrition. He holds a Doctorate of Nutripathy and is a New York State certified Clinical Nutritionist. He is a professional member of the International and American Association of Clinical Nutritionists, The American College of Nutrition and is a member of the Scientific Advisory Board for the Clinical Nutrition Certification Board.Learn more at www.health-truth.com, The Biamonte Center Facebook page www.facebook.com/The-Biamonte-Center-241435772676317/, and one YouTube www.youtube.com/channel/UCiss7csT6pBnPAyeNA5AbDQ. You can also find his book, The Candida Chronicles, on Amazon. Find out more about the All In Running Club at www.allinhealthandwellness.com/all-in-running-clubVisit ConfidenceThroughHealth.com to find discounts to some of our favorite products.Follow me via All In Health and Wellness on Facebook or Instagram.Find my books on Amazon: No More Sugar Coating: Finding Your Happiness in a Crowded World and Confidence Through Health: Live the Healthy Lifestyle God DesignedProduction credit: Social Media Cowboys

Heart disease was thought to be a men's health problem for decades, but now we've learned that women die of heart attacks at twice the rate of men and women of color are nearly 50% more likely to die from heart disease. Part of the problem is that women and their doctors often don't consider heart disease as a factor in their medical care. Dr. Stacey Rosen is on the Scientific Advisory Board of the Women's Heart Alliance, a non-profit co-founded by Barbra Streisand. Dr. Rosen joins us to explain the risks and signs of heart disease that are different in women, and how to make sure both you and your doctors are keeping a lookout at every stage in your life. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Drew Ramsey, MD @DrewRamseyMD is a board certified psychiatrist, author, and mental health advocate. His work focuses on clinical excellence, nutritional psychiatry, male mental health and creative media. He is an assistant clinical professor of psychiatry at Columbia University College of Physicians and Surgeons and founded the Brain Food Clinic, a digital mental health clinical practice. His work has been featured by The New York Times, The Wall Street Journal, Lancet Psychiatry, The Today Show, BBC, and NPR and he has given three TEDx talks. He is co-author of the Antidepressant Food Scale and created the first e-courses on Nutritional Psychiatry education for the public and clinicians. His books Eat to Beat Depression and Anxiety (Harperwave 2021), Eat Complete, 50 Shades of Kale, and The Happiness Diet explore the connections between mental health and nutrition. He is on the Advisory Board at Men's Health, the Editorial Board at Medscape Psychiatry, and the Scientific Advisory Board of the anti-stigma nonprofit Bring Change To Mind. He lives in Jackson, Wyoming with his wife and two children. In today's episode, Dr. Ramsey and I discuss how food can contribute to our mood. He emphasizes the importance of nourishing the brain with the right foods to optimize mental health and potentially prevent and treat mental health concerns. Dr. Ramsey also highlights the significance of educating ourselves about the nutrients our brains need, such as magnesium, vitamin E, and omega-3 fats, and where to find them in our diets. In addition to food, we touched on the topic of alternative treatments for mental health, particularly ketamine. Dr. Ramsey explained ketamine's history, its use in treating depression, and its potential to open up neuroplastic windows in the brain, offering new pathways for healing. This episode is a must-listen for anyone interested in the powerful connection between what we eat and how we feel. Dr. Ramsey's expertise and passion for nutritional psychiatry is truly inspiring, and his insights could be the key to unlocking a happier, healthier life for you! Dr. Ramsey's Instagram: https://www.instagram.com/drewramseymd/ Dr. Ramsey's Youtube: https://www.youtube.com/@DrewRamseyMD/featured Dr. Ramsey's Latest Book: https://drewramseymd.com/books-publications/eat-to-beat-depression-and-anxiety/ Healing the Modern Brain course: https://learn.drewramseymd.com/masterclass-order-evergreen/ For $250 off your Lumebox, preorder for their updated model launching this January 2024, using this link: https://justingredients.us/products/lumebox-red-light?_pos=1&_sid=e88ca0cba&_ss=r

ERP is widely considered the gold standard treatment for OCD. Unfortunately, very few people with OCD receive this type of therapy due to many external factors. It can take up to 17 years for someone with OCD symptoms to receive any treatment let alone the best one. Also, many people with OCD are unaware of ERP's existence or how it even works.  We explain what OCD is and is not and address some common reasons people don't seek help for OCD.  Join us as our host, Gabe Howard, speaks with Dr. Patrick McGrath, the clinical director of NOCD.com, an app-based platform that specializes in bringing ERP to those who need it. Special thanks to NOCD for graciously sponsoring this episode. Learn more at treatmyocd.com. To read the transcript or see show notes, please visit the official episode page. Our guest, Dr. Patrick B. McGrath serves as the Chief Clinical Officer for NOCD, an app-based platform for the treatment of OCD, leading their teletherapy services across the world. He opened Intensive Outpatient, Partial Hospital, and Residential Treatment Programs for Anxiety Disorders, School Refusal, and OCD. He is also a member of the Scientific Advisory Board of the International OCD Foundation. He is a Fellow of the Association for Behavioral and Cognitive Therapies. He authored “Don't Try Harder, Try Different,” and “The OCD Answer Book.” He was featured on Discovery Health Channel's, “Panic” and on three episodes of TLC's “Hoarding; Buried Alive.” Our host, Gabe Howard, is an award-winning writer and speaker who lives with bipolar disorder. He is the author of the popular book, "Mental Illness is an Asshole and other Observations," available from Amazon; signed copies are also available directly from the author. Gabe makes his home in the suburbs of Columbus, Ohio. He lives with his supportive wife, Kendall, and a Miniature Schnauzer dog that he never wanted, but now can't imagine life without. To book Gabe for your next event or learn more about him, please visit gabehoward.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

 Welcome to The H.V.M.N. Podcast with your host, Dr. Latt Mansor! In this insightful episode, we have the privilege of interviewing Dr. Michael Biamonte, the visionary founder of the Biamonte Center for Clinical Nutrition. Dr. Biamonte is not only a distinguished clinical nutritionist but also a co-creator of BioCybernetics, a groundbreaking computer software program originally designed for aerospace applications. This innovative program has the remarkable ability to analyze blood work, mineral tests, and various lab tests to pinpoint precise imbalances within the body. With over three decades of dedicated practice, Dr. Biamonte is committed to enhancing the lives of his patients and guiding them back to a healthy, vibrant existence. He holds a doctorate in naturopathy and is a New York State-certified clinical nutritionist. Moreover, he's a respected professional member of international and American clinical nutritionist associations, the American College of Nutrition, and sits on the Scientific Advisory Board for the Clinical Nutrition Certification Board. In this enlightening episode, we delve into crucial topics, including candida overgrowth – how to identify it and strategies for treatment. Dr. Biamonte also sheds light on the most common pitfalls people encounter when taking supplements for their health and offers invaluable insights on how to avoid them. Don't miss this opportunity to gain valuable knowledge from Dr. Michael Biamonte, a true expert in the field of clinical nutrition. Tune in now and empower yourself with the information you need to lead a healthier life!     Dr. Biamonte on Instagram https://www.instagram.com/drbiamonte/ Twitter: https://twitter.com/hvmn and https://twitter.com/LattMansor Instagram: https://www.instagram.com/hvmn/ and https://www.instagram.com/lattmansor/  TikTok: https://www.tiktok.com/@hvmn and https://www.tiktok.com/@lattmansor  Feedback form: https://forms.gle/7KH87sEqaRa1z19B6 H.V.M.N. Podcast Fam: We're giving you an exclusive offer. You are some of our most loyal fans, and we want to give you a special reward. Use HVMNPOD20 to get 20% off your next H.V.M.N. order.